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1 ABSTRACT 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers 
worldwide. Radical surgical resection combined with chemotherapy, the only 
potentially curative treatment, is possible in only a small proportion of 
patients. Although overall survival is poor, marked variation exists between 
patients of the same tumor stage. New biomarkers could be helpful in 
predicting prognosis. Despite considerable research on potential biomarkers, 
since the discovery of CA19-9, none has gained a role in clinical practice. 
Identification of new biomarkers to predict PDAC patient outcome more 
accurately and to enhance our knowledge of the molecular mechanisms 
behind the disease is crucial. Differential diagnosis between PDAC and 
chronic pancreatitis (CP) can be challenging. A pancreatic mass can prove to 
be benign or malignant. A clear preoperative diagnosis would be valuable for 
patients to avoid unnecessary and extensive surgery. The standard serum-
based marker for diagnosis of PDAC, CA19-9, has diagnostic limitations 
because it can be normal in patients with localized disease or high in patients 
with benign pancreatic disease, including CP. 
 
The aim of this thesis was to explore, tissue expression of tumor biomarkers 
in PDAC. The prognostic significance of these biomarkers in patient survival 
was evaluated. In each study, we used different biomarkers: podocalyxin 
(PODXL), PROX1, β-catenin, UCHL5, and REG4. In the last study, we also 
evaluated the diagnostic significance of serum REG4 levels in patients with 
PDAC and in those with CP. Immunohistochemical expression of tumor 
markers was evaluated in 154 surgical specimens and serum REG4 level in 
130 samples from PDAC patients treated between 2000 and 2011. The CP 
control group comprised 34 patients who underwent resection because of 
suspicion of malignancy.  
 
PODXL, PROX1, β-catenin, and UCHL5 were independent prognostic 
markers. High tissue expression of PODXL prognosticated poor survival 
among PDAC patients compared with low tissue expression, whereas high 
tissue expression of both PROX1 and β-catenin was associated with increased 
survival. Positive nuclear UCHL5 expression was an independent factor for 
favorable prognosis. REG4 failed to be an independent marker of prognosis 
in PDAC, but serum REG4 levels were higher in PDAC than in CP suggesting 
its utility in differential diagnosis.   
 
These studies provide novel knowledge of potential prognostic tumor 
markers in PDAC. Moreover, we identified a serum biomarker, REG4, that 
may be useful in differential diagnosis between PDAC and CP.  
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2   FINNISH SUMMARY 
Haiman duktaalinen adenokarsinooma on yksi huonoennusteisimmista 
syöpätaudeista. Suomessa haimasyöpä aiheuttaa kolmanneksi eniten 
syöpäkuolemia. Radikaali kirurgia yhdistettynä sytostaattihoitoon on ainoa 
mahdollinen parantava hoitomuoto, mutta vain pieni osa haimasyöpäpotilaista 
soveltuu tällaiseen hoitoon. Vaikka taudin yleinen ennuste on huono, saman 
levinneisyysasteen potilailla ennuste saattaa vaihdella paljonkin. Uudet 
biomarkkerit auttaisivat potilaiden ennusteen arvioinnissa. Vaikka lukuisia 
potentiaalisia markkereita on tutkittu vuosikausien ajan, yhtään markkeria ei 
ole otettu kliiniseen käyttöön CA 19-9:n löytämisen jälkeen. On välttämätöntä 
löytää uusia biomarkkereita, jotta haimasyöpäpotilaiden ennustetta voidaan 
arvioida tarkemmin ja täsmällisemmin. Tämä parantaisi myös tietämystä 
haimasyövän kehittymisen taustasta molekyylitasolla. Erotusdiagnostiikka 
haimasyövän ja kroonisen haimatulehduksen välillä voi ajoittain olla hankalaa. 
Haiman kuvantamistutkimuksissa nähdyt muutokset voivat olla pahan- tai 
hyvänlaatuisia. Tarkka diganoosi ennen mahdollista leikkausta hyödyttäisi 
potilaita, joita ei välttämättä tällöin tarvitsisi altistaa raskaalle kirurgiselle 
hoidolle. CA19-9, jota käytetään laajasti leikkausta edeltävässä diagnosoinnissa, 
on osin ongelmallinen, koska se voi olla normaalitasolla syövästä tai koholla 
hyvänlaatuisesta muutoksesta huolimatta. 
 
Tutkimuksemme tavoitteena oli tutkia kudosmarkkereiden ennusteellista arvoa 
haimasyövässä. Jokaisessa osatyössä tutkimme eri biomarkkereita. Tutkitut 
markkerit olivat podokalyksiini, PROX1, β-catenin, UCHL5 ja REG4. 
Viimeisessä osatyössä tutkimme myös REG4:n diagnostista arvoa haimasyövän 
ja kroonisen pankreatiitin välillä. Markkereiden immunohistokemiallinen 
ilmentyminen arviotiin 154 leikatusta haimasyöpäpotilaasta vuosina 2000-
2011. Kroonisen pankreatiitin kontrolliryhmään kuului 34 potilasta, jotka oli 
leikattu haiman pahanlaatuisen kasvainepäilyn takia.  
 
PODXL, PROX1, β-catenin ja UCHL5 olivat itsenäisiä ennustemarkkereita. 
Korkea PODXL:n kudosilmentyminen ennusti huonompaa selviytymistä 
syövästä verrattuna matalaan ilmentymiseen. Korkea PROX1:n ja β-cateninin 
kudosilmentyminen sen sijaan ennusti parempaa selviytymistä. Positiivinen 
UCHL5:n ilmentyminen liittyi myös parempaan ennusteeseen verrattuna 
negatiiviseen ilmentymiseen. REG4:n osalta taudin ennusteessa ei ollut 
merkittäviä eroja kudosilmentymisen mukaan, mutta REG4:n pitoisuudet olivat 
merkittävästi korkeammat haimasyövässä kuin kroonisessa 
haimatulehduksessa. Tutkimuksemme toi uutta tietoa potentiaalisista 
ennusteellisista biomarkkereista. Löysimme myös uuden mahdollisen 
biomarkkerin, REG4:n, jota voidaan mahdollisesti käyttää tulevaisuudessa 
apuna diagnostiikassa. 
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4 ABBREVIATIONS 
5-FU 5-fluorouracil 
AJCC American Joint Committee on Cancer  
APC adenomatous polyposis coli 
AUC area under the curve 
BMI body mass index 
CA celiac axis 
CA 19-9 carbohydrate antigen 19-9  
CC Creative Commons 
CEA carcinoembryonic antigen 
CHA common hepatic artery 
CI  confidence interval 
CP chronic pancreatitis 
CRC colorectal cancer 
CRP C-reactive protein 
CSS cancer-specific survival 
CT computed tomography 
CTNNB1 protein β-catenin encoding gene 
DM diabetes mellitus 
DNA deoxyribonucleic acid 
DUB deubiquitinating enzyme 
ECM extracellular matrix 
ERCP endoscopic retrograde cholangiopancreatography 
EUS endoscopic ultrasound 
FNA fine-needle aspiration 
GDA gastroduodenal artery 
GM-CSF granulocyte-macrophage colony-stimulating factor 
HCC hepatocellular carcinoma 
HES9 monoclonal antibody against human embryonic stem cells 
HR hazard ratio  
IBD inflammatory bowel disease 
IHC immunohistochemistry 
IQR interquartile range 
IPMN intraductal papillary mucinous neoplasm  
ISGPS International Study Group of Pancreatic Surgery  
IVC inferior vena cava 
LNR lymph node ratio 
mAb monoclonal antibody 
MCN mucinous cystic neoplasm 
MRCP magnetic resonance cholangiopancreatography 
MRI magnetic resonance imaging 
mRNA messenger ribonucleic acid 
11 
NCCN National Comprehensive Cancer Network 
pAb polyclonal antibody 
PanIN pancreatic intraepithelial neoplasia 
PCR polymerase chain reaction 
PDAC pancreatic ductal adenocarcinoma 
PET positron emission tomography 
PODXL podocalyxin-like 1 protein 
PROX1 prospero homeobox protein 1 
PSC pancreatic stellate cell 
PTC papillary thyroid cancer 
PV portal vein 
r  correlation coefficient  
REG4 regenerating islet-derived protein 4 
RNA ribonucleic acid 
ROC receiver operating characteristic 
SE standard error 
SMA superior mesenteric artery 
SMV superior mesenteric vein  
TCF/LEF T-cell factor/lymphoid enhancer factor  
TGF-β transforming growth factor-beta 
TMA tissue microarray 
TNM tumor-node-metastasis 
UCHL5 ubiquitin c-terminal hydrolase L5 
UPS ubiquitin-proteasome system 
US ultrasonography
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5 INTRODUCTION 
Pancreatic malignancy has a notoriously dim prognosis, with an overall 5-
year survival of less than 8% [1]. In the United States, it is the fourth leading 
cause of cancer-related deaths, and in Finland it is the third (Finnish Cancer 
Registry). Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% 
of pancreatic cancers, and it metastasizes rapidly in its early stages. There are 
also other tumors of the pancreas with different prognoses and treatment 
methods, but this study focuses entirely on PDAC.  
 
The underlying causes of pancreatic cancer are still to be resolved. 
Accumulating gene mutations leading to dysplasia and malignant tumor 
development are regarded as the most common cause [2,3]. Smoking and 
chronic pancreatitis are some of the most important risk factors. Sadly, no 
suitable population-based screening tests exist. At the early stage of PDAC, 
patients’ symptoms are often vague and may be completely missing. 
Nevertheless, early detection would be critical for patient outcome. Curative 
treatment is based on radical surgical resection followed by chemotherapy. 
However, only a minor proportion of patients, roughly 10-20%, are eligible 
for surgery because of concomitant advanced disease or metastases [2].  
 
The prognosis of PDAC is based on stage of the disease, tumor-free resection 
margins, histological type and differentiation of the tumor, lymph node 
metastases, and tumor size. Although overall survival is poor, marked 
variation exists between patients of the same tumor stage. New diagnostic, 
prognostic, and predictive biomarkers are urgently needed. Since the 
discovery of biomarker CA19-9, no biomarker has gained a role in clinical 
practice despite comprehensive research. 
 
The aim of this study was to examine the prognostic significance of five tissue 
biomarkers in surgically treated patients. We also evaluated the differential 
diagnostic usefulness of REG4 between PDAC and chronic pancreatitis.  
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6 REVIEW OF THE LITERATURE 
6.1 EPIDEMIOLOGY 
Pancreatic cancer is the world’s 12th most common cancer type with nearly 340 
000 new cases annually. However, it is the seventh leading cause of cancer 
deaths globally, with incidence and mortality rates being almost identical [4]. In 
developed countries, pancreatic cancer causes almost 190 000 deaths every 
year, with incidence of 8.6 in men and 5.9 in women per 100 000. In less 
developed areas, the recorded incidence rate is slightly lower, from 2.4 to 3.3 
per 100.000, and an almost identical mortality rate [5]. In the United States, 
pancreatic cancer is the fourth leading cause of cancer deaths, with incidence of 
14.1 in men and 10.9 in women and overall mortality rates of 12.5 and 9.5, 
respectively [1,6]. 
 
According to the Finnish Cancer Registry, pancreatic cancer age-adjusted 
incidence rate in Finland in 2015 was 9.0 for men and 7.1 for women per 
100.000 inhabitants and more than 1000 new cases (Finnish Cancer Registry, 
available at www.cancerregistry.fi). With almost the same mortality rate, 8.8 in 
men and 6.9 in women, pancreatic cancer is the third leading cause of cancer 
deaths (Figure 1). At Helsinki University Hospital, the 5-year survival rate was 
22% for those patients resected for PDAC between 2000 and 2013 [7]. 
However, the overall survival for pancreatic cancer, including all subtypes of 
pancreatic malignancies, remains at about 5% in Finland according to the 
Finnish Cancer Registry. With distant metastases, PDAC is fatal, as 5-year 
survival rate drops to near zero [1]. 
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Figure 1.  Annual incidence and mortality of pancreatic cancer by time 
period. Source: Finnish Cancer Registry, Cancer Statistics at 
www.cancerregistry.fi, updated 13 March 2018.  
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6.2 ETIOLOGY 
6.2.1 RISK FACTORS 
 
Pancreatic cancer is a multifactorial and complex disease.  Lifetime risk for 
pancreatic cancer is less than 1%, being more frequent in developed countries 
than in less developed areas [5]. A family history of pancreatic cancer, 
smoking, chronic pancreatitis, and advanced age are regarded as constant 
risk factors for pancreatic cancer. Other risk factors include diabetes 
mellitus, excessive alcohol consumption, obesity, Western dietary habits, and 
non-O blood group [3,8,9]. 
6.2.1.1 Genetic predisposition/family history 
About 10% of pancreatic cancer patients have a familial basis [10-12]. Risk 
for pancreatic cancer is roughly doubled with one first-degree relative 
diagnosed with the disease, rising to even 57-fold in families with four or 
more affected members [11,13]. Pancreatic cancer can develop in many 
genetic syndromes, which, however, only partly cover the cases of familial 
pancreatic cancers. The most common syndromes with mutated genes and 
risk ratios are described in Table 1. 
 
 
Table 1.  Hereditary cancer syndromes with increased risk for pancreatic 
cancer and affected genes. The table is modified from earlier studies 
[3,10,14].  
Genetic syndrome Affected gene(s) Risk ratio 
Familial breast and ovarian cancer BRCA2, BRCA1 3.5-10 
Familial atypical multiple mole 
melanoma syndrome 
CDKN2A (p16) 9-47 
Peutz-Jeghers syndrome STK11 (LKB1) 132 
Hereditary pancreatitis PRSS1, SPINK1 50-80 
Hereditary non-polyposis colorectal 
cancer (Lynch syndrome) 
Multiple 9 
Familial adenomatous polyposis (FAP) APC 4.5 
Familial pancreatic cancer PALB2 6 
Familial pancreatic cancer 
(monoallelic); ataxia-telangiectasia 
(biallelic) 
ATM Unknown 
 
16 
6.2.1.2 Smoking 
Smoking is a recognized risk factor for pancreatic cancer. Current cigarette 
smoking leads to a 1.8-3.4-fold risk relative to non-smokers [15-17]. The risk 
ratio increases with the number of cigarettes smoked. Former smokers have 
approximately a 1.2-fold risk relative to non-smokers. The risk for former 
smokers remains elevated for 10-20 years after cessation. The starting age of 
cigarette smoking has no effect on the risk. 
6.2.1.3 Chronic pancreatitis 
Pancreatitis, an inflammation of the pancreas, destroys normal pancreatic 
tissue and can lead to irreversible changes in pancreatic cells. Accumulating 
evidence shows that longstanding existing chronic pancreatitis is a strong 
risk factor for pancreatic cancer [18-20]. The latent time between diagnosis 
of chronic pancreatitis and pancreatic cancer can be as long as 10-20 years.  
The risk can increase to 5-fold with unspecified pancreatitis, to 13- to 16-fold 
with chronic pancreatitis, and to even 69-fold with hereditary pancreatitis 
[18,20]. The risk seems to be highest in newly diagnosed (<2 years) chronic 
pancreatitis patients, with the risk diminishing over time [20]. Even though 
the link between chronic pancreatitis and pancreatic cancer is strong, only 
about 5% of patients with chronic pancreatitis develop pancreatic cancer over 
a 20-year period.  
6.2.1.4 Diabetes mellitus 
Diabetes mellitus (DM) leads to elevated blood glucose levels and can be 
divided into insulin deficiency (type 1 DM) and insulin resistance (type 2 
DM) types. Type 2 DM is associated with obesity and unhealthy nutritional 
habits, and its incidence is rapidly rising. DM is associated with a twofold 
increased risk for pancreatic cancer compared with healthy subjects [21,22]. 
The risk is highest for a recently diagnosed DM and decreases over time. An 
elevated risk remains even 20 years after DM diagnosis. Up to 40% of the 
patients with pancreatic cancer report new-onset DM within three years 
prior to the cancer diagnosis [23,24]. However, the absolute risk is low, since 
less than 1% of newly diagnosed patients with DM develop pancreatic cancer 
during a five-year follow-up [23,25]. 
6.2.1.5 Other (lifestyle-related) risk factors 
Risk for pancreatic cancer increases with age, being very uncommon in 
patients under 40 years. The median age of onset is 65-75 years. Over 80% of 
patients diagnosed are aged between 60 and 80 years. 
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Obesity is associated with an increased risk for pancreatic cancer, even 
without DM [26]. It increases the risk 25-50% compared with normal-weight 
individuals, regardless of diabetes or smoking status [27]. The risk ratio 
appears to depend on body mass index (BMI): the higher the BMI, the 
greater the risk for pancreatic cancer. With a stepwise rise of 5 kg/m2 in BMI, 
the overall risk increases 2-12% [27]. In addition to obesity, low physical 
activity and such dietary habits as high intake of red meat and low intake of 
fruits and vegetables and polyunsaturated fatty acids may have an effect on 
the increased risk [28]. 
 
Excessive alcohol consumption as an independent risk factor for pancreatic 
cancer has been under debate. Current evidence indicates that heavy alcohol 
consumption (>50 g alcohol per day) can increase the risk of pancreatic 
cancer [29]. The most recent meta-analysis suggests that even alcohol 
consumption of ≥24 g per day may increase the risk [30].  
6.2.2 SCREENING 
Screening for pancreatic cancer is problematic. The malignant nature of 
invasive pancreatic cancer and the perception that most patients present 
with advanced stage disease lead to efforts to identify early invasive 
pancreatic cancers and pre-invasive lesions. However, identifying pre-
invasive lesions may result in overdiagnosis and treatment of patients. In 
addition, pancreatic cancer has a rather low incidence, and there is no simple 
and accurate screening method. For that reason, possible screening ought to 
be focused on high-risk individuals with genetic predisposition syndrome 
associated with pancreatic cancer, family history of pancreatic cancer, or 
patients more than 50 years old with several known risk factors such as new-
onset diabetes and smoking history [31].  
 
However, screening for pancreatic cancer in high-risk individuals is 
controversial in assessing the survival of patients [32-34]. There is 
disagreement about the age to initiate screening and about the best imaging 
method for screening, but endoscopic ultrasound (EUS) and magnetic 
resonance-based imaging (MRI/MRCP) appear to be the most suitable 
methods [35].  
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6.3 PATHOGENESIS 
6.3.1 PRECURSOR LESIONS 
Pancreatic ductal adenocarcinoma is the most common pancreatic 
malignancy. PDAC develops from non-invasive precursor lesions, most 
commonly from epithelial proliferations within the pancreatic ducts, referred 
to as pancreatic intraepithelial neoplasias (PanINs) [36]. PanINs are non-
invasive and microscopic (<5 mm) lesions classified by their epithelial atypia. 
PanIN lesions are traditionally divided into three grades: PanIN-1A/B, 
PanIN-2, and PanIN-3 [37,38]. The higher the PanIN grade, the closer the 
lesion is to progressing to invasive carcinoma (Figure 2). However, in 2015, 
consensus recommendations suggested using a two-class grading (low vs. 
high grade) [39]. Low-grade PanINs (PanIN-1) are common with increasing 
age, and high-grade PanINs (PanIN-3) are usually present in the pancreas 
with invasive cancer.  
 
 
 
Figure 2. PanIN progression model showing genetic alterations. PanIN = 
pancreatic intraepithelial neoplasia. Reprinted [36] with permission of the 
American Association for Cancer Research.  
 
Some adenocarcinomas can develop from macroscopic cystic tumors or 
precursors: from intraductal papillary mucinous neoplasms (IPMNs) or from 
mucinous cystic neoplasms (MCNs). IPMNs are mucinous cysts affecting the 
pancreatic duct system and are more than 5-10 mm in size [40]. They are 
categorized into low-grade (adenoma), intermediate/moderate (borderline), 
or high-grade (carcinoma in situ) based on the degree of dysplasia in the 
epithelium. In addition, multiple histological subtypes are identified [41].  
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MCNs are less common than IPMNs and occur mainly in women. They are 
usually located in the body or tail of the pancreas and do not communicate 
with the pancreatic ducts [42,43]. MCNs also are categorized as IPMNs, and 
their key feature is ovarian-type stroma underlying the epithelium, which 
differentiates MCNs from other mucin-producing neoplasms. International 
guidelines have been established to standardize and direct the follow-up and 
treatment of these cystic neoplasms [44-46] . 
6.3.2 GENE MUTATIONS  
The genetic basis of pancreatic cancer is complex and heterogeneous, 
creating a challenge for treatment. However, four major genetic alterations 
are responsible for PDAC. KRAS is the most frequently mutated oncogene. 
Mutations in KRAS occur in over 90% of the tumors, which leads to 
increased proliferation, cell survival, and suppressed apoptosis [47,48]. 
CDKN2A, encoding a protein with a critical role in cell-cycle regulation, is the 
most frequently altered tumor suppressor gene in more than 90% of PDACs 
[49,50]. KRAS mutations are common also in PanINs, suggesting they may 
be one of the first alterations in pancreatic tumorigenesis, whereas 
inactivation of CDKN2A does not typically occur in the low-grade precursor 
lesions [51]. Somatic mutations in the TP53 tumor suppressor gene occur in 
about 75% of pancreatic malignancies. The protein encoded by TP53 has a 
crucial role in apoptotic signaling and control of DNA damage during the cell 
cycle [52]. As the fourth most commonly mutated gene, tumor suppressor 
SMAD4 is mutated in about 55% of cases, regulating the transforming 
growth factor-beta (TGF-β) signaling pathway [53,54]. 
 
In recent years, an explosion of knowledge about the genetic alterations 
underlying the pathogenesis of pancreatic cancer has occurred. Studies have 
identified, through genome sequencing, mutations in hundreds of genes 
[50,55]. The difficulty is in identifying which genes drive or enhance the 
tumorigenesis of pancreatic neoplasms.   
6.3.3 TUMOR MICROENVIRONMENT 
The microenvironment of pancreatic adenocarcinoma is complex, affecting 
both tumor growth and therapeutic response. It is characteristically stroma-
rich, consisting of proliferating myofibroblasts (pancreatic stellate cells 
(PSCs)), extracellular matrix (ECM) such as type I collagen and hyaluronic 
acid, and many types of inflammatory cells including macrophages, mast 
cells, lymphocytes, and plasma cells [56]. The stroma functions not only as a 
mechanical barrier, but also forms a dynamic environment involved in tumor 
formation, progression, invasion, and metastasis [57,58]. Pancreatic cancer 
is characterized by low microvascular density with limited perfusion, leading 
to intratumoral hypoxia. The fibrous stroma may contribute to reduced blood 
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flow, and constant production of ECM increases the interstitial pressure, 
compressing the capillary vessels and impairing drug delivery [59,60].  
 
An additional relevant feature of the microenvironment of pancreatic 
adenocarcinoma is restraining of immune surveillance and creating an 
inflammatory response that supports tumorigenesis through cross-talk 
between tumor cells and immune cells [61]. Immunosuppressive regulatory 
T-lymphocytes and myeloid cells are recruited to the tumor stroma from the 
early stages of tumor formation, which leads to a block in T-cell-mediated 
antitumor immunity. This recruitment is induced by oncogenic activation of 
KRAS in pancreatic cells, resulting in production of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [62,63].  
 
The central role of the tumor microenvironment makes it an important focus 
for novel therapy targets. Therapies aimed at depleting or modifying cellular 
and acellular components of the stroma are intriguing and they may provide 
a new approach for immune-based or other targeted therapies [63,64].  
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6.4 DIAGNOSIS 
6.4.1 CLINICAL PRESENTATION 
Most pancreatic cancers do not elicit symptoms in the early stage. The 
possible symptoms depend on the location of the tumor within the pancreas. 
Most symptoms are vague and non-specific such as nausea, vomiting, weight 
loss, or abdominal discomfort. Tumors in the head of the pancreas (60-70% 
of cases) can cause obstructive cholestasis and jaundice, which may lead to 
earlier detection of the disease. Abdominal pain occurs more commonly in 
later stages, and it typically feels dull and deep in the epigastrium. As the 
cancer infiltrates the retroperitoneum, back pain may appear. New-onset DM 
and degenerating glucose balance with diagnosed DM can be a manifestation 
of the failure of the endocrine pancreas. Weight loss can arise from anorexia, 
maldigestion from pancreatic ductal obstruction, or cachexia. Infrequently, 
obstruction of the pancreatic duct can provoke acute pancreatitis. Deep or 
superficial venous thrombosis may occur as a sign of malign disease. Other 
rare symptoms may be panniculitis, liver function abnormalities, gastric 
outlet obstruction, increased abdominal girth, or depression [3,9,65].  
 
Physical examination may reveal upper abdominal resistance, jaundice (first 
detectable in the sclera), lymphadenopathy, hepatomegaly, painlessly 
enlarged gallbladder (Courvoisier’s sign), and ascites. Abnormalities in 
routine blood tests are non-specific and include hyperglycemia, anemia, and 
abnormalities in liver function tests [8].  
6.4.2 IMAGING 
Transabdominal ultrasonography (US) can be used as a standard or first-line 
diagnostic imaging modality in a patient with upper abdominal pain or to 
evaluate dilatation of the bile and pancreatic ducts. US is safe, readily 
available, and cost-effective, but it lacks the sensitivity and specificity to 
detect pancreatic tumors.  
 
When suspecting a pancreatic tumor, multiphase-multidetector computed 
tomography (CT) with pancreatic protocol and with intravenous 
administration of constrast material is the imaging technique of choice for 
the initial evaluation. Overall, CT detects solid pancreatic masses with a 
sensitivity of 90% and a specificity of 99% [66,67]. However, in small 
pancreatic lesions (<2 cm), the sensitivity of CT imaging drops to 70% or 
below [68]. CT enables visualization of the primary tumor in relation to 
blood vessels, namely superior mesenteric artery (SMA), celiac axis, superior 
mesenteric vein (SMV), and portal vein (PV), but also to adjacent and distant 
organs. By CT imaging, the initial staging and management plan can 
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generally be confirmed. In diagnosis of vascular invasion by pancreatic 
cancer, a sensitivity of 71% and a specificity of 92% are reported [69].  
 
Magnetic resonance imaging (MRI) combined with magnetic resonance 
cholangiopancreatography (MRCP) can be used instead of CT if the patient 
cannot tolerate intravenous contrast of CT. MRI seems to be as sensitive and 
specificas CT in assessing the vascular invasion [69]. No significant 
difference in evaluating the resectability of pancreatic cancer is present 
between MRI and CT [70]. A disadvantage of MRI is its unsuitability for 
tissue sampling.  
 
Endoscopic retrograde chloangiopancreatography (ERCP) demonstrates the 
anatomy of pancreatic and bile ducts, and it can be used as a treatment tool 
in patients with obstructive jaundice, in whom an endoscopic stent is needed 
to relieve obstruction [71]. ERCP also allows brushing and lavage of the duct 
system, providing cells for diagnosis.  
 
Some patients require additional diagnostic imaging. Endoscopic 
ultrasonography (EUS) can be used in patients with suspected pancreatic 
cancer, but with no visible mass in CT scan. EUS may be superior to CT in 
tumor detection and staging, but is comparable in nodal staging and 
evaluating resectability [72,73]. It is useful in detecting small tumors (<2 cm) 
that are undetected by other imaging modalities [72]. For EUS, a meta-
analysis showed sensitivity of 72% and specificity of 90% for T1-2 stages and 
sensitivity of 90% and specificity of 72% for T3-4 tumors [74]. When 
available, it is the preferred method of acquiring tissue for cytology or 
histological diagnosis. If cytology is needed, CT-guided fine-needle aspiration 
(FNA) can be carried out. EUS combined with FNA reaches a sensitivity of up 
to 90% for detecting pancreatic cancer [75]. 
 
Postiron emission tomography (PET) is not routinely used in diagnosis or 
staging since it has no obvious advantage compared with current diagnostic 
methods [76]. However, it may provide additional information after CT if 
distant metastases are suspected, but the lesions remain indefinable [77,78]. 
For defining nodal stage (N status), PET is equal to CT in sensitivity [78].  
PET scanning seems not to show any additional advantage in differential 
diagnostics between chronic pancreatitis and pancreatic cancer relative to 
other imaging techniques [76]. If none of the imaging techniques clarify the 
clinical stage of the pancreatic cancer, a diagnostic laparoscopy or 
laparotomy can be performed to determine metastatic spread.   
6.4.3 DIAGNOSTIC TUMOR MARKERS 
Research on potential diagnostic tumor markers in PDAC has been intense 
over the years. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic 
 23 
antigen (CEA) are the only routinely used markers in diagnosis and follow-
up. However, they both have limited sensitivity and specificity and they 
cannot be used in early diagnosis. Numerous potential tumor markers have 
been investigated, but none has achieved a role in clinical practice [79-83]. In 
order to describe the extent of studies on potential tumor markers, more 
than 2500 genes are showed to be involved in pancreatic cancer in more than 
2500 studies [84].  
 
CA 19-9, also known as sialylated Lewis A antigen, is an antibody binding to 
the tumor surface marker sialyl Lewis a [85]. In Caucasian populations, 
about 5-10% are negative for Lewis a and express no CA 19-9. Thus, negative 
values do not rule out pancreatic cancer. Sensitivity of CA 19-9 for pancreatic 
cancer is about 70-90% and specificity 68-91% [86]. In non-jaundiced 
patients, CA 19-9 may complement other diagnostic methods. However, it 
must be borne in mind that several benign diseases, such as chronic and 
acute pancreatitis, liver cirrhosis, cholangitis, and obstructive jaundice, may 
elevate CA 19-9 levels. Also, in other gastrointestinal cancers, such as bile 
duct, gastric, colorectal, esophageal, and hepatocellular carcinomas, levels of 
CA 19-9 can be increased [87]. In addition, CA 19-9 lacks sensitivity in small-
diameter (<3 cm), and dedifferentiated PDACs. Even though CA 19-9 fails to 
meet the criteria for a diagnostic marker, it is a beneficial tool in PDAC 
assessement. Increased pretreatment CA 19-9 levels >100 kU/l may predict 
unresectable or metastasized disease, and a decrease in post-treatment CA 
19-9 level may be associated with prolonged survival and responsiveness to 
chemotherapy [88,89].  
 
CEA is usually used in colorectal cancer as a diagnostic and prognostic 
marker, but it can also be elevated in gastric and pancreatic cancers. In 
pancreatic cancer, a sensitivity of 40-45 % and a specificity of 81-89% are 
reported [90,91].  
 
In addition to the conventional biomarkers described above, a great array of 
novel biomarkers has been introduced, including micro-RNAs and other 
non-coding RNAs, multimarker panels, proteomics, cytokines, and genetic 
and epigenetic markers [80-83]. While some progress has been made, the 
evidence for their efficacy still remains insufficient.  
 
6.4.4 DIFFERENTIAL DIAGNOSIS BETWEEN PANCREATIC CANCER 
AND CHRONIC PANCREATITIS 
Differential diagnosis between pancreatic cancer and chronic pancreatitis 
(CP) can be challenging, especially in patients with pancreatic mass, which 
can prove to be either benign or malignant [92]. Mass-forming chronic 
pancreatitis should preoperatively be differentiated from pancreatic cancer in 
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order to possibly avoid unnecessary and extensive surgery. Unfortunately, no 
blood test exists for chronic pancreatitis, and the disease is mainly diagnosed 
by imaging and symptoms.  
 
Some cases of mass-forming pancreatitis are autoimmune-based. 
Autoimmune pancreatitis can be divided into two subtypes depending on the 
relation to IgG4. Type 1 autoimmune pancreatitis is characterized by 
lymphoplasmacytic sclerosing histological feature, and it is an IgG4-related 
disease. In contrast, type 2 features neutrophilic infiltration of the epithelium 
of the pancreatic duct in histology and is not related to IgG4 [93]. 
Autoimmune pancreatitis and pancreatic cancer share many clinical features 
such as age over 60 years, obstructive jaundice, new-onset diabetes, and 
elevated levels of serum tumor markers [94]. The differential diagnosis 
between autoimmune pancreatitis and pancreatic cancer is based on clinical, 
serological, imaging, and pathological findings. Imaging techniques include 
CT/MRI, ERCP, and EUS-guided FNA [95].  
 
In non-autoimmune chronic pancreatitis, serum marker CA 19-9 has its 
diagnostic limitations and is not sufficient alone to differentiate pancreatic 
cancer from CP [86]. With CT and MRI imaging, CP is characterized by 
calcifications of the pancreas, pancreatic duct dilatation, and enlargement or 
atrophy of the pancreas [75]. In the early stages of CP, these findings may be 
absent, however. Typically, pancreatic adenocarcinoma is an ill-defined 
hypodense mass on CT. Smaller cancers (<2 cm) can be isodense, which 
makes it difficult to detect these cancers. Furthermore, conventional CT may 
have difficulties in differentiating between inflammatory and neoplastic 
masses. When using EUS for diagnosis, abnormalities found at the earliest 
stages of developing pancreatic cancer can be identical to CP [96]. 
 
Despite developments in established imaging modalities (MRI, CT, EUS, and 
PET), differential diagnosis between inflammatory and neoplastic pancreatic 
masses remains a challenge. New imaging technologies, such as contrast-
enhanced EUS, EUS elastography, and molecular imaging, are on their way, 
but they lack standardized protocols and are in a too early stage of 
development for clinical practice [75,92]. 
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6.5 TREATMENT 
6.5.1 STAGING AND OVERVIEW OF TREATMENT 
To evaluate resectability, PDAC is staged based on imaging according to tumor-
node-metastasis (TNM) classification. The American Joint Committee on 
Cancer (AJCC) has recently published a new version (8th edition) of the staging 
system for pancreatic cancer (Table 2) [97]. A few major modifications were 
made from the older 7th edition staging system, which was introduced in 2010 
[98]. First, instead of designating extrapancreatic invasion, which can be 
difficult to predict accurately before surgery, T3 tumors are now defined as 
larger than 4 cm. Second, nodal involvement has been revised from a binary 
system to a three-class categorization based on extent of nodal involvement: 
N0, N1 (1-3 positive regional lymph nodes), and N2 (≤4 positive regional lymph 
nodes) [99,100]. 
 
Surgical resection with oncological treatment is regarded as the only curative 
treatment and can result in significantly longer survival than the other 
treatment options. In general, stages I and II are considered resectable, and 
stage IV unresectable. Stage III can be considered both. Pancreatic cancer 
without distant metastasis can be divided into three more clinically relevant 
categories: resectable, borderline resectable, and locally advanced. Certain 
parameters, based on CT imaging, determine PDAC resectability [68,101,102].   
 
A resectable tumor shows no evidence of extrapancreatic disease and there is a 
patent SMV or PV. Also, a normal tissue plane is identified between the tumor 
and the celiac trunk, common hepatic artery (CHA), or SMA. With a borderline 
resectable tumor, there is involvement of SMV or PV with tumor contact ≥180° 
or bilateral narrowing or occlusion of the vein not exceeding the inferior border 
of the duodenum [89]. There can also be evidence of tumor abutment <180° 
without showing deformity or stenosis against celiac trunk, CHA, or SMA. In a 
locally advanced tumor, which is considered unresectable, SMV or PV is 
bilaterally narrowed or occluded exceeding the inferior border of the duodenum 
[89]. Furthermore, arterial involvement of the celiac trunk, CHA, or SMA is 
advanced with tumor contact or invasion >180°. If there is evidence of 
metastatic spread (typically to the liver, peritoneum or lung), the tumor is 
considered unresectable.  
 
 
 
 
 
 
 
26 
Table 2.  Staging system for pancreatic cancer according to the American 
Joint Committee on Cancer (AJCC) 7th and 8th edition. Used with permission 
of the American College of Surgeons, Chicago, Illinois, USA. The original and 
primary source for this information is the AJCC Cancer Staging Manual, 7th 
(2010) and 8th (2017) edition published by Springer International Publishing 
[97,98]. 
Stage Primary 
tumor 
(T) 
Regional 
lymph 
nodes 
(N) 
Distant 
metastases 
(M) 
Characteristics 
AJCC 7th edition 
IA T1 N0 M0 Tumor limited to pancreas 
≤2 cm  
IB T2 N0 M0 Tumor limited to pancreas 
<2 cm 
IIA T3 N0 M0 Tumor extends beyond 
pancreas without 
involvement of CA or SMA  
IIB T1-T3 N1 M0 Regional lymph node 
metastasis 
III T4 Any N M0 Tumor involves CA or 
SMA (unresectable 
primary tumor) 
IV Any T Any N M1 Distant metastasis 
AJCC 8th edition 
IA T1 N0 M0 Maximum tumor diameter 
≤2 cm 
IB T2 N0 M0 Maximum tumor diameter 
between 2-4 cm 
IIA T3 N0 M0 Tumor diameter >4 cm 
IIB T1-T3 N1 M0 Metastasis in 1-3 regional 
lymph nodes 
III Any T N2 M0 Metastasis in ≥4 regional 
lymph nodes 
 T4 Any N M0 Tumor involves CA or 
SMA (unresectable 
primary tumor) 
IV Any T Any N M1 Distant metastasis 
Abbreviations: CA = celiac axis; SMA = superior mesenteric artery 
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The International Study Group of Pancreatic Surgery (ISGPS) has defined 
borderline resectable pancreatic cancer in their consensus statement 
according to the National Comprehensive Cancer Network’s (NCCN) 
previous recommendation [102]. Patients with borderline resectable 
pancreatic cancer are a challenging subgroup, because they are in the stage 
between a straightforward resectable disease and a technically unresectable 
disease. In the presence of venous involvement (SMV or PV), exploration, 
resection, and possible reconstruction of the vein is recommended, if 
achievable. On the other hand, arterial resections are associated with 
increased morbidity and mortality and should not be performed routinely. 
They are acceptable in selected cases, but in general, patients with arterial 
infiltration should be first treated with neoadjuvant therapy and then re-
evaluated for surgery after the treatment depending on patients’ performance 
status [102]. NCCN has just recently updated the criteria for resectability 
status [103]. The criteria are described in detail in Table 3. 
 
Patients with borderline resectable pancreatic cancer may benefit from an 
attempt to downsize the tumor with neoadjuvant therapy [104]. This has the 
potential to elicit a positive tumor response and to downstage patients 
eligible for surgery [105]. Neoadjuvant therapy can detect patients with 
rapidly progressing disease who would not benefit from surgical resection. In 
contrast, tumor response rates to current neoadjuvant treatments are not 
high, and delaying surgical resection can also lead to progression of the 
disease. Because of this, patients undergoing neoadjuvant therapy should 
have restaging by imaging before the planned surgery [9]. 
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Table 3. Criteria defining resectability status according to National 
Comprehensive Cancer Network (NCCN) guidelines, version 2.2017. Table 
modified [103] and reproduced with permission by NCCN. 
Resectability 
status 
Arterial Venous 
Resectable No arterial tumor contact (CA, 
SMA, or CHA) 
No tumor contact with 
SMV or PV; or ≤180° 
contact without vein 
contour irregularity 
Borderline 
resectable 
Pancreatic head: 
Solid tumor contact with 
? CHA allowing resection 
and reconstruction 
? SMA of ≤180° 
? Variant arterial 
anatomy (presence and 
degree of tumor contact 
should be noted) 
Pancreatic body/tail: 
Solid tumor contact with 
? CA of ≤180° 
? CA of >180° without 
involvement of aorta, 
and with intact GDA 
Solid tumor contact with 
? SMV or PV of 
>180° 
? SMV or PV ≤180° 
with contour 
irregularity, or 
thrombosis, but 
suitable for 
complete resection 
and reconstruction 
? IVC 
Unresectable Distant metastasis 
Pancreatic head: 
Solid tumor contact with 
? SMA >180° 
? CA >180° 
? First jejunal SMA 
branch 
Pancreatic body/tail: 
Solid tumor contact with 
? SMA or CA >180° 
? CA and aortic 
involvement 
? Unreconstructible 
SMV/PV due to 
tumor involvement 
or occlusion  
? Contact with most 
proximal draining 
jejunal branch into 
SMV 
Abbreviations: CA = Celiac axis; SMA = Superior mesenteric artery; CHA = 
Common hepatic artery; SMV = Superior mesenteric vein; PV = Portal vein; GDA = 
Gastroduodenal artery; IVC = Inferior vena cava 
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A significant proportion of pancreatic cancer patients develop jaundice due 
to biliary obstruction, which can be relieved by endoscopic stenting via 
ERCP. Preoperative biliary drainage should only be carried out in patients 
with active cholangitis, or if the resection cannot be scheduled within 2 weeks 
of diagnosis [105]. Metallic stents may have fewer obstruction- and stent-
related complications than plastic stents [106,107]. If the life expectancy of 
the patient is less than 4 months, a plastic stent can be inserted. In patients 
who are candidates for neoadjuvant therapy, plastic or metallic stents may be 
used, with a preference for metallic stents [108]. The disadvantage of metallic 
stents is that they are expensive and their exchange is more challenging than 
with plastic stents. Staging laparoscopy is recommended to avoid 
unnecessary laparotomies, although a pancreatic tumor is staged as 
resectable by imaging, especially in large tumors and in cases with high CA 
19-9 level, because distant metastases are found in 10-20% during the 
operation [109-111].  
 
6.5.2 PANCREATIC SURGERY 
Radical surgery combined with oncological treatment is the only potentially 
curative treatment. However, while 20% of the patients are candidates for 
surgery at the time of diagnosis, many of these patients are found to have 
microscopically positive margins at the time of operation [1,112]. Surgery and 
possible adjuvant therapy can extend the median survival time from about 5 
months (all stages at diagnosis) to 25 months [7,113,114]. The 5-year survival 
of surgically treated patients can reach about 20% [7,100]. Perioperative 
mortality from pancreatic resection, ranging from 1% to 4%, is rather low at 
most centers, especially in high-volume centers, despite the invasive and 
demanding surgery [7,115,116]. Several studies show that centralization of 
these operations into high-volume hospitals leads to better patient outcome, 
fewer complications, and lower mortality [115,117,118]. With pancreatic 
resection, the goal is to achieve total extirpation of the tumor with clear 
resection margins ≥1 mm (R0 resection). There is great variation in achieving 
the R0 resection, which a range from 26% to 74% [119].  
 
The location and size of the tumor determine the type of surgery. Since the 
majority of operable pancreatic tumors localize in the head of pancreas, the 
standard surgical procedure is pancreaticoduodenectomy (Whipple 
procedure) [120]. The procedure consists of removing the head of the 
pancreas, duodenum, proximal part of jejunum, gallbladder and its cystic 
duct, common bile duct (ductus choledochus), distal part of stomach 
(antrum), and regional lymph nodes. During the operation three 
anastomoses are performed: pancreaticojejunostomy, 
choledochojejunostomy, and gastrojejunostomy with possible entero-enteral 
anastomosis. The alternative method is to perform 
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pancreaticoduodenectomy by a pylorus-preserving method. Current evidence 
shows no relevant differences in mortality, morbidity, and survival between 
these two operations [121]. The dissection can be extended along the right 
hemi-circumference of the SMA to the coeliac trunk to possibly improve 
clearance and the rate of R0 resection [105]. 
 
For patients with tumors in the body or tail of the pancreas, distal 
pancreatectomy is usually performed. This procedure includes the resection 
of the body and the tail of the pancreas and usually the spleen. At times, total 
pancreatectomy is required. A laparoscopic approach in surgery for 
pancreatic cancer is used in specialized, high-volume centers. The exact role 
of the laparoscopic approach in pancreatic cancer surgery remains 
undefined, since there is lack of multi-center randomized trials and 
standardization of the procedure [122-124]. One recently published 
randomized trial showed no significant differences in postoperative overall 
complications between laparoscopic and open pancreatoduodenectomy 
[125]. By far, open surgery remains the gold standard of care.  
 
Standard lymphadenectomy during pancreaticoduodenectomy is 
recommended. It comprises the supra- and infrapyloric lymph nodes, the 
lymph nodes in the anteriosuperior group along the CHA, along the bile and 
cystic duct, on the posterior aspect of the superior portion of the head of 
pancreas, on the inferior aspect of the head of pancreas, on the right lateral 
side of SMA, and on the anterior surface of the superior and inferior portion 
of the head of pancreas [126]. For tumors of the body and tail of the 
pancreas, removal of the following lymph nodes is recommended:  lymph 
nodes at the splenic hilum, along the splenic artery, and on the inferior 
margin of the pancreas [126]. Further, standard lymphadenectomy should 
include ≥12 lymph nodes to allow adequate pathologic staging. The total 
number of lymph nodes examined, and lymph node ratio (LNR) (number of 
involved lymph nodes/number of lymph nodes examined) should be 
reported. Along with the new 8th AJCC staging edition, LNR has been 
replaced by N1/N2 status. Attempts to improve survival by extended 
lymphadenectomy have failed to show survival benefit [127], and the patients 
who underwent extended lymphadenectomy have considerably increased 
perioperative complications [128,129]. Hence, extended lymphadenectomy is 
not recommended [126]. 
6.5.3 ONCOLOGICAL TREATMENT 
6.5.3.1 Neoadjuvant therapy 
The goal of neoadjuvant therapy (given prior to operation) is to downsize the 
tumor from unresectable disease to resectable disease, and, ultimately, to 
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improve survival of patients. Whether neoadjuvant therapy is given to 
resectable pancreatic cancer patients or not is considered on a case-to-case 
basis. Resection rates of up to 70% after neoadjuvant therapy with initially 
radiographically resectable PDAC are reported [104,130]. Pancreatic 
resection after neoadjuvant therapy seems to be safe [131]. Neoadjuvant 
therapy with gemcitabine or FOLFIRINOX (a chemotherapy combination of 
folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin), followed by 
chemoradiation (combination of capecitabine and radiotherapy), if suitable, 
is considered if the tumor is local but primarily borderline resectable or 
unresectable [105].  
6.5.3.2 Adjuvant therapy 
Postoperative adjuvant therapy reduces the risk for recurrence and improves 
patient outcome. Chemotherapy with either 5-FU or gemcitabine after 
pancreatic resection is considered standard adjuvant therapy after surgery, 
and it improves disease-free and overall survival of PDAC patients [132-134]. 
5-FU and gemcitabine seem to be equally effective, with median overall 
survival of 23.0 and 23.6 months, respectively [113]. The aim of adjuvant 
therapy after surgery for PDAC is to introduce 6 months (six cycles) of 
postoperative adjuvant chemotherapy, which can be initiated up to 12 weeks 
after surgery [135]. Gemcitabine combined with erlotinib seems not to 
improve disease-free or overall survival of PDAC patients after radical 
surgery relative to gemcitabine treatment alone [136]. Adjuvant therapy with 
gemcitabine plus capecitabine compared with gemcitabine alone may have a 
favorable effect on overall survival (median overall survival 28.0 vs. 25.5 
months) [137]. Recently, S-1 treatment (combination of tegafur (prodrug of 
fluorouracil), gimeracil, and oteracil potassium) was showen to be superior to 
gemcitabine treatment in a Japanese study (median overall survival 46.5 vs. 
25.5 months) [138]. In periampullary cancer, adjuvant therapy after surgery 
with either 5-FU or with gemcitabine has provided a survival benefit 
compared with observation only, with median survival of 43.1 and 35.2 
months, respectively [139]. 
 
Adjuvant radiotherapy is mainly used in the United States and rarely in 
Europe. The benefit of radiotherapy is controversial [3,68,105,132]. In brief, 
adjuvant radiotherapy is not generally recommended.  
6.5.3.3 Palliative therapy 
The goal of palliative therapy is to prolong life expectancy and to reduce 
symptoms in metastatic or unresectable disease. When the tumor is 
unresectable and locally advanced, regardless of the treatment method, the 
average overall survival of these patients remains modest (approximately one 
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year). The standard care has been 6 months of gemcitabine. By adding 
radiotherapy or chemoradiation to chemotherapy alone, the median overall 
survival seems not to be improved [140-142].  
 
In advanced or metastasized disease, much effort has been directed to 
finding a gemcitabine chemotherapy combination to improve survival. The 
results have been unsatisfactory. According to a meta-analysis in 2013, 
combination therapy compared with gemcitabine alone significantly 
improved overall survival, but the advantage was only marginal [143]. 
Furthermore, combination therapy induced more treatment-related toxicity. 
Promising results are reported with gemcitabine treatment combined with 
nab-paclitaxel, which prolongs the overall survival by about two months (8.5 
vs. 6.7 months) [144]. Also, gemcitabine combined with capecitabine 
improved median overall survival by three months (10.3 vs. 7.5 months) 
relative to gemcitabine alone [145]. 
 
However, major improvement has been achieved with FOLFIRINOX therapy, 
which is superior to gemcitabine alone in terms of efficacy [146]. Median 
overall survival in the FOLFIRINOX group was 11.1 months, whereas in the 
group treated with gemcitabine it was 6.8 months. This multimodal 
chemotherapy has more toxicity, unfortunately, which limits its usage. 
FOLFIRINOX is an option for the treatment of patients with metastatic 
pancreatic cancer and good performance status.  
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6.6 PROGNOSIS 
6.6.1 PATIENT-RELATED PROGNOSTIC FACTORS 
The incidence of pancreatic cancer increases with age. However, it is most 
frequently diagnosed among people aged 65-74 years, with a median age of 
70 years at diagnosis. With increasing age, also comorbidities become more 
common. Patients older than 80 years may have an increased incidence of 
postoperative mortality, morbidity, and cardiac complications and longer 
hospital stays than younger patients [147,148]. In general, pancreatic surgery 
can be recommended only in selected patients older than 80 years. 
Pancreatic cancer is slightly more common in men than in women, and 
mortality is also slightly higher in men [1,114].  Diabetes, common among 
pancreatic cancer patients, is associated with worse survival [149,150]. 
6.6.2 TUMOR-RELATED PROGNOSTIC FACTORS 
Tumor stage and resectability are the main determinants of prognosis in 
pancreatic cancer [100]. From the resected tumor specimen, many 
prognostic factors can be determined. Radicality of the resection is one of the 
key elements. The goal is to achieve radical resection (R0), meaning a ≥1 mm 
resection margin of tissue without macroscopic or microscopic tumor 
infiltration.  Other prognostic factors of the tumor specimen include tumor 
size (T stage), lymph-node metastasis (N stage), LNR, differentiation grade, 
and neural and vascular invasion [116,151-153].  
6.6.3 PROGNOSTIC SERUM AND TISSUE TUMOR MARKERS 
Tissue biomarkers have been widely investigated over the years with the aim 
of enhancing prognostication and prediction of clinical outcome after 
surgery. Despite numerous studies evaluating the potential prognostic value 
of biomarkers, no biomarker is routinely used in clinical practice. There are a 
few meta-analyses and reviews recapitulating the current knowledge of these 
potential biomarkers [154,155] (Table 4). However, the tissue biomarkers 
studied in this thesis have not been investigated before in PDAC.  
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Table 4.  Independent prognostic and predictive markers in patients with 
pancreatic ductal adenocarcinoma. This table is reproduced with 
modifications [154] with permission from the Britsh Journal of Surgery. 
Studies with <70 patients were excluded from the original table. 
Biomarker Reference Year n Hazard ratio (95% CI) P 
Self-sufficiency in growth signals 
Cyclin E Skalicky 2006 118 1·71 (1·12-2·63) 0·013 
Ki-67 Karamitopo 2010 77 3·63 (1·9-6·9) < 0·001 
HER2 Komoto 2009 129 1·81 (1·07-3·04) 0·026 
IGF2BP3 Schaeffer 2010 127 3·34 (1·92-8·96) 0·051 
Midkine Maeda 2007 75 2·14 (1·29-3·71) 0·003 
Insensitivity to growth-inhibitory signals 
MUC2 Takikita 2009 120 1·6 (1·1-2·4) < 0·05 
 Juuti 2003 76 0·6 (0·3-1·0) < 0·05 
SMAD4 Tascilar 2001 249 0·74 (0·55-0·99) 0·042 
SMAD7 Wang 2009 71 0·39 (0·18-0·83) 0·014 
TGF-ß1 Nio 2005 91 0·49 (0·30-0·79) 0·003 
Evasion of apoptosis 
IEX-1 Sasada 2008 78 0·66 (0·50-0·86) 0·002 
XAF1 Huang 2010 89 0·48 (0·28-0·82) 0·007 
Sustained angiogenesis 
CD34 Fujioka 2001 104 1·94 (1·12-3·36) 0·019 
COX-2 Juuti 2006 128 1·6 (1·1-2·4) 0·018 
 Matsubayashi 2007 299 1·41 (1·08-1·84) 0·01 
Dkk3 Fong 2009 114 0·61 (0·40-0·94) 0·024 
PEDF Uehara 2004 80 0·39 (0·22-0·70) 0·002 
Tissue factor Nitori 2005 113 2·01 (1·21-3·37) 0·008 
VEGFR1 (FLT-1) Chung 2006 76 0·10 (0·02-0·49) 0·004 
Tissue invasion and metastasis 
ALCAM/CD166 Kahlert 2009 97 2·87 (1·69-4·87) < 0·001 
Caveolin-1 Suzuoki 2002 79 1·88 (1·04-3·39) 0·036 
CCR7 Nakata 2008 89 1·95 (1·04-3·64) 0·036 
Cytokeratin 20 Matros 2006 103 2·41 (1·09-2·25) 0·016 
CXCR4 Maréchal 2009 71 2·54 (1·27-5·10) < 0·001 
Dysadherin Shimamura 2003 125 2·17 (1·14-4·14) 0·019 
E-cadherin Shimamura 2003 125 0·55 (0·35-0·85) 0·008 
Ezrin Yeh 2005 73 2·73 (1·65-5·37) 0·03 
Galectin-3 Shimamura 2002 104 0·49 (0·29-0·81) 0·006 
GDNF Ben 2010 94 2·10 (1·23-3·58) 0·007 
HMGA1 Liau 2008 89 12·47 (2·71-57·52) 0·001 
L1-CAM Ben 2010 94 2·05 (1·20-3·49) 0·009 
LI-cadherin Takamura 2003 102 0·49 (0·28-0·86) 0·01 
MMP-7 Yamamoto 2001 70 4·85 (1·22-10·8) 0·022 
MUC4 Saitou 2005 135 1·96 (1·13-3·38) 0·017 
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S100A4 Oida 2006 72 1·81 (1·01-3·27) 0·048 
Escape from immune surveillance 
RCAS1 Hiraoka 2002 80 3·09 (1·33-7·21) 0·009 
Epigenetic 
modifications 
     
Histone 
H3K4me2 
Manuyakorn 2010 140 0·42 (0·27-0·65) < 0·001 
Histone 
H3K9me2 
Manuyakorn 2010 140 0·62 (0·40-0·96) 0·032 
Histone H3K18ac Manuyakorn 2010 140 0·60 (0·40-0·92) 0·018 
Histone 
H3K27me3 
Wei 2008 165 0·49 (0·32-0·75) 0·001 
Resistance to chemotherapy 
hENT1 Farrell 2009 91 0·40 (0·22-0·75) 0·03 
Other markers 
CD133 Maeda 2008 80 2·15 (1·21-3·87) 0·009 
HOXB2 Segara 2005 74 2·69 (1·39-5·20) 0·003 
LMO2 Nakata 2009 164 0·43 (0·28-0·67) < 0·001 
p97 Yamamoto 2004 83 2·42 (1·11-2·26) < 0·01 
Thymidylate 
synthase 
Hu 2003 132 1·66 (1·05-2·63) 0·029 
TROP2 Fong 2008 197 1·8 (1·1-3·1) 0·01 
 
 
6.6.3.1 CA19-9 
Besides being used as a diagnostic marker, CA 19-9 has been studied also as a 
prognostic marker. Most clinics use the value of 37 kU/l as the standard cut-
off point. At this value, CA 19-9 seems not to be an independent prognostic 
factor. For patients with localized disease undergoing resection, the 
preoperative CA 19-9 is generally a poor prognostic biomarker because of 
possible falsely elevated levels in the case of biliary obstruction. Preoperative 
CA 19-9 levels are most informative when there is no biliary obstruction or 
when it has been decompressed and the serum bilirubin has normalized.  
With postoperative values over 180, CA 19-9 can function as an independent 
prognostic factor [156,157]. Also, the decrease in CA 19-9 level from the 
baseline value during chemotherapy predicts prognosis [158,159]. Lack of 
decrease in CA 19-9 levels during chemotherapy seems to have the strongest 
negative impact on survival. However, patients with very high preoperative 
CA 19-9 levels may live as long as patients with normal levels, assuming that 
the CA 19-9 level falls into the normal range after resection [160]. 
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6.6.3.2 Podocalyxin 
Podocalyxin-like 1 protein (PODXL) regulates cell-to-cell adhesions through 
charge-repulsive effects, but also contributes to cell morphology. It is a 
transmembrane glycoprotein closely related to the hematopoietic stem cell 
marker CD34 and to endoglycan [161]. PODXL is normally expressed in 
hematopoietic progenitor cells [162], vascular endothelial cells [163], and 
renal podocytes [164]. It was first identified in the kidney in helping to 
maintain filtration pathways [165]. When normal PODXL expression is lost, 
it is associated with glomerulopathies – mainly with nephrotic syndrome 
[166].  
 
PODXL overexpression has been described in many cancer types such as 
leukemia and breast, colorectal, urothelial bladder, hepatocellular, prostate, 
gastric, esophageal, and lung cancers [167-176]. It is an independent factor 
for poor outcome in renal cell carcinoma and, breast, colorectal, gastric, and 
esophageal cancers [168-170,174,175,177,178]. PDAC cells are generally 
positive for PODXL, but other adenocarcinomas of the biliary and 
gastrointestinal tract are mainly negative [179]. Membranous PODXL 
expression correlates with poor prognosis in CRC and urothelial bladder 
cancer [169-171,178]. Polyclonal antibody is commercially available for 
PODXL. High cytoplasmic expression of PODXL by a novel monoclonal 
antibody has been shown to also be a marker of poor prognosis in CRC [180]. 
At the time of our study of PODXL, no reports existed about the prognostic 
significance of PODXL in PDAC. Since then, two studies have been 
published, in which PODXL has been shown to be associated with 
unfavorable prognosis in pancreatic cancer [181,182]. 
6.6.3.3 PROX1 and β-catenin 
The Wnt/β-catenin signaling pathway takes part in regulating cellular 
processes, such as organ development and differentiation, and tissue 
homeostasis in adults [183]. Aberrant signaling can lead to cancer 
development [184]. A key molecule in this pathway is β-catenin, which is an 
intracellular protein localizing in cell membrane, cytoplasm, and nucleus. 
Binding of Wnt ligand to its receptors inhibits β-catenin phosphorylation, 
which allows β-catenin to escape from degradation. β-catenin accumulates in 
the cytoplasm and translocates to the nucleus, where it activates a target gene 
expression via interaction mainly with members of the T-cell 
factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors 
[185,186]. In CRC, most tumors have mutations in key regulatory factors of 
the Wnt/β-catenin pathway such as adenomatous polyposis coli (APC) or 
protein β-catenin encoding gene (CTNNB1) [185].  
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In PDAC, the role of the Wnt/β-catenin signaling pathway is controversial 
because of varying and sometimes paradoxical effects in the pancreas. 
Although genetic alterations of the Wnt signaling pathway are involved in 
PDAC [50], mutations of APC or CTNNB1 are rare [187]. 
Immunohistochemical membranous expression of β-catenin is correlated 
with loss of tumor differentiation in PDAC [188]. β-catenin may be 
upregulated in PDAC by both immunohistochemistry and polymerase chain 
reaction (PCR) [187,189]. Prognostic significance of β-catenin expression in 
PDAC has been investigated in a few studies with rather short follow-up 
times [190-193].  
 
Transcription factor PROX1 has been established to be a downstream target 
of the Wnt/β-catenin pathway in colorectal tumor neoplastic transformation 
and progression [194]. PROX1 is a transcriptional regulator and a part of the 
homeobox transcription factor family [195] with a key role in the 
development of the central nervous system [196], lens [197], liver [198], 
pancreas [198], lymphatic system [199], and heart [200]. In addition, it has 
oncogenic properties through alterations in its expression. Depending on the 
tissue, it can act either as a tumor suppressor or as an oncogene [201]. 
PROX1 is less expressed in pancreatic cancer cells than in the normal 
exocrine pancreas [202]. Gene expression level of PROX1 has been shown to 
be lower in patients with survival of less than 6 months than in patients with 
longer survival [202]. Recently, high PROX1 expression was demonstrated to 
predict better prognosis in gastric cancer [203]. 
6.6.3.4 UCHL5 
The ubiquitin-proteasome system (UPS) is an essential cellular protein 
degradation system. Protein substrates are targeted for degradation by 
polyubiquitination [204]. Ubiquitins are small molecules that adhere to 
protein polypeptide chains and target them for degradation by the 
proteasome. Before degradation, the attached polyubiquitin chains are 
removed by deubiquitinating enzymes (DUBs). The human genome contains 
around 80 known DUBs, from which, some 40 of which are associated with 
various types of cancer [205,206]. UCHL5/Uch37, a cysteine protease from 
the family of ubiquitin C-terminal hydrolases (UCHs), is one of the three 
proteasome-associated DUBs. It interacts with the 26S-proteasome subunit, 
inducing its DUB activity [207]. Disturbances in this function are associated 
with malignant processes.  
 
UCHL5 expression levels and intracellular location vary in both cancerous 
and normal tissues (The Human Protein Atlas Project, available at: 
www.proteinatlas.org/ENSG00000116750-401 UCHL5/tissue, accessed 23rd 
of December 2017). In esophageal squamous cell carcinoma, hepatocellular 
carcinoma, and epithelial ovarian cancer, high UCHL5 expression is reported 
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to be associated with poor survival and increased cancer recurrence [208-
210].  In contrast, strong, but also negative, UCHL5 expression is correlated 
with better patient survival in lymph node-positive rectal cancer [211]. Before 
our study, UCHL5 expression has not been reported in PDAC.   
 
6.6.3.5 REG4 
The regenerating islet-derived (REG) proteins are a group of small secretory 
proteins involved in regulation of cell regeneration and proliferation 
[212,213]. Among the four REG families (1 to 4), REG4 is the most recently 
discovered. It was identified and isolated in 2001 from a cDNA library of 
ulcerative colitis tissue [214]. REG4 is physiologically expressed in the colon 
and small intestine with high expression in enteroendocrine cells [215,216], 
but not in pancreatic islets. Upregulation of REG4 expression occurs in 
inflammatory bowel diseases (IBDs) [214,215], but its expression is also 
increased in many gastrointestinal cancers. In CRC, high tissue expression of 
REG4 is associated with poor prognosis [217-219], but positive tissue REG4 
expression has been shown to be associated with better prognosis in non-
mucinous CRC [220]. In gastric cancer, high tissue REG4 expression predicts 
poor survival [221] and possibly promotes peritoneal metastasis [222]. In 
gallbladder cancer, positive tissue REG4 expression favors better prognosis 
[223]. Overexpression of REG4 is also expected to play a role in gastric [224] 
and colorectal [225] carcinogenesis.  
 
Several reports show REG4 expression in pancreatic cancer cells to be 
increased relative to normal pancreatic cells, and REG4 to promote 
invasiveness and proliferation of cancer cells [226-228]. In addition, REG4-
expressing pancreatic tumors tend to grow larger, while knockdown of REG4 
expression leads to tumor shrinking or impaired growth of cancer cells in 
vivo and in vitro [226,229]. More intense resistance to radiation and 
chemotherapy (mainly gemcitabine) occurs in pancreatic cancer cell models 
in vivo and in vitro along with REG4 expression [229,230]. The prognostic 
value of REG4 expression in PDAC is unknown. Tissue REG1A/B expression 
is associated with prognosis of PDAC [231].  
 
Elevated REG4 serum levels and positive immunohistochemical staining are 
present in PDAC patients, suggesting that REG4 may serve as a diagnostic 
marker [226,231,232].  
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7 AIMS OF THE STUDY 
 
? To evaluate the relationship of PODXL with clinicopathological 
parameters and its role as a prognostic marker in PDAC by two 
different antibodies 
 
? To examine the association of PROX1 and β-catenin with 
clinicopathological parameters and to determine their role as 
prognostic markers in PDAC 
 
? To explore UCHL5 tumor tissue expression in PDAC and to assess 
UCHL5 expression as a prognostic marker in PDAC 
 
? To evaluate tumor tissue and serum REG4 expression in PDAC and to 
investigate the value of serum REG4 level in differential diagnosis 
between patients with PDAC and those with CP. 
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8 PATIENTS AND METHODS 
8.1 PATIENTS 
Between 2000 and 2011, altogether 188 PDAC patients underwent surgery 
with curative intent at the Department of Surgery, Helsinki University 
Hospital, Finland. Of these, 34 patients were excluded from this study: 22 
who received neoadjuvant chemotherapy, 8 who were eventually diagnosed 
with stage IV disease, and 4 in whom stage was not reliably documented. 
Other types of pancreatic cancer (e.g. cystic or mucinous malignancies) were 
not included in the study. Patients’ median age at surgery was 64 (range 39-
83) years. The median follow-up was 2.0 (range 0.2-13.1) years. The TNM 
staging was based on the 7th edition of the AJCC staging system for 
pancreatic cancer. For Study IV, the control group for serum REG4 analysis 
consisted of 34 patients with histopathologically verified CP who underwent 
pancreatic surgery because of suspicion of malignancy between 2000 and 
2008. The median age for this patient group was 54 (range 35-74) years. 
Clinical data were derived from patient records. The Finnish Population 
Registry provided survival data, and Statistics Finland provided cause of 
death for those deceased. Clinicopathological characteristics of the study 
population are described in Table 5. 
 
All studies followed the tenets of the Declaration of Helsinki and were 
approved by the Surgical Ethics Committee of Helsinki University Hospital, 
and the National Supervisory Authority of Welfare and Health (Valvira).  
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Table 5.  Clinicopathological characteristics of the study population for 
immunohistochemistry. 
 PDAC study population 
n(%) 154 
Age, years  
<65 77  (50.0) 
≥65 77 (50.0) 
Gender  
Male 84 (54.5) 
Female 70 (45.5) 
T  
1 11 (7.1) 
2 39 (25.3) 
3 101 (65.6) 
4 3 (1.9) 
N  
0 48 (31.2) 
1 106 (68.8) 
Stage (AJCC 7th edition)  
IA 9 (5.8) 
IB 18 (11.7) 
IIA 20 (13.0) 
IIB 104 (67.5) 
III  3 (1.9) 
Lymph node ratio  
<20 % 118 (77.6) 
≥20 % 34 (22.4) 
Missing 2 
Histological grade  
1 18 (11.8) 
2 110 (71.9) 
3 25 (16.3) 
Missing 1 
Perineural invasion  
Yes 101 (77.1) 
No 30 (22.9) 
Missing 23 
Perivascular invasion  
Yes 43 (34.1) 
No 83 (65.9) 
Missing 28 
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8.2 TUMOR TISSUE SPECIMENS (STUDIES I-IV) 
Formalin-fixed and paraffin-embedded tumor samples were obtained from 
the archives of the Department of Pathology, Helsinki University Hospital, 
Finland. Experienced pathologists re-evaluated all samples for confirmation 
of the histopathological diagnosis of PDAC. Representative areas of tumor 
specimens were defined and marked on hematoxylin- and eosin-stained 
slides for preparation of tissue microarray blocks (TMA). In order to evaluate 
TMA representativeness compared with whole tissue blocks, six 1.0-mm 
cores were taken from each tumor block from both the invasive front and the 
central part of the tumor with a semiautomatic tissue microarrayer (Tissue 
Arrayer 1, Beecher Instruments Inc., Silver Spring, MD, USA). In Study II, we 
also chose 13 whole tumor tissue blocks and the corresponding lymph node 
metastases from the patient cohort to compare PROX1 expression in the 
tumor and in its lymph node metastases. 
8.3 IMMUNOHISTOCHEMISTRY AND ANTIBODIES 
Tumor-tissue microarray blocks were freshly cut into 4-µm sections. After 
deparaffinization in xylene and rehydration through a gradually decreasing 
ratio of ethanol to distilled water, slides were treated in a PreTreatment 
module (Lab Vision Corp., Fremont, CA, USA) in antibody-specific buffer for 
20 minutes at 98°C to retrieve antigen. Staining of sections was performed in 
an Autostainer 480 (Lab Vision Corp.) by the Dako REAL EnVision 
Detection system, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, 
Denmark) or by ImmPRESS HRP Polymer Detection Kit, Peroxidase, Anti-
Goat IgG (Vector Laboratories, Burlingname, CA, USA). Tissues were 
incubated with the chosen antibody for one hour or overnight at room 
temperature. Antibodies and variations in pre-treatment, dilution, and 
positive control are described in Table 6.  
 
The novel monoclonal in-house antibody (HES9) used in the study I 
recognizes amino acid residues 189-192 of PODXL. The polyclonal antibody 
(HPA2110, Atlas Antibodies, Stockholm, Sweden) recognizes amino acid 
recidues 278-415. The specificity of the polyclonal antibody has been 
validated by Western blotting and protein arrays, and PODXL protein 
expression has been mapped by immunohistochemistry in normal tissues 
and common cancers [233,234].  
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Table 6. Antibodies for immunohistochemistry. 
Antibody Clone Source Pre-treatment Dilution Positive 
control 
PODXL 
HES9 
mAb In-house Tris-HCl  
(pH 8.5) 
1:800 colon 
PODXL pAb, HPA 
2110 
Atlas 
Antibodies, 
Sweden 
Tris-HCl  
(pH 8.5) 
1:250 colon 
PROX1 pAb, Anti-
human 
PROX1 
Antibody  
R&D Systems, 
USA  
Tris-HCl  
(pH 8.5)/Tris-
EDTA (pH 9.0) 
1:1500 Colon, 
lymph node 
β-catenin pAb, Beta-
Catenin 
Antibody 
Invitrogen, 
Thermo Fisher 
Scientific, USA 
Tris-HCl  
(pH 8.5)/Tris-
EDTA (pH 9.0) 
1:500 Colon, 
lymph node 
UCHL5 pAb, 
HPA005908 
Sigma Aldrich, 
USA 
Tris-HCl   
(pH 8.5) 
1:800 Colon 
REG4 mAb In-house Tris-HCl   
(pH 8.5) 
1:50 Colon, 
lymph node 
Abbreviations: mAb = monoclonal antibody; pAb = polyclonal antibody 
 
 
The monoclonal antibody has previously been described in detail [180]. In 
brief, mice were immunized with the undifferentiated human embryonic 
(hEs) stem cell line SA167 (Cellartis, Gothenburg, Sweden, 
www.cellartis.com). By conventional hybridoma technology, hybridoma cell 
lines were established that produced monoclonal antibodies against hES 
cells. The target antigen was identified as PODXL. Both epitopes occur in the 
extracellular part of the PODXL molecule. The epitope sequence of the 
HPA2110 matches 100% three protein coding PODXL splice variants  
(PODXL 001, 005, and 201, The Human Protein Atlas). The fourth splice 
variant provides an 87% match (PODXL 202). The epitope sequences of the 
HES9 matches 100% all splice variants. 
 
8.4 STAINING PATTERN AND SCORING OF SAMPLES 
Immunostaining was in each project independently scored by two 
investigators (Studies I, II, and IV: Kapo Saukkonen and Jaana Hagström; 
Study III: Leena Arpalahti and Jaana Hagström), and they were blinded to 
clinical data and outcome. Differences in scoring were discussed until 
consensus was reached. The highest score of each patient was regarded as 
representative for analysis in Studies I, II, and IV. In Study III, the median 
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score of each patient served in further analysis because of variation of 
expression in pancreatic tumor tissue. 
 
In Study I, PODXL expression by monoclonal antibody (mAb) HES9 was 
evenly distributed in the cytoplasm and was often granular in appearance. By 
polyclonal antibody (pAb), PODXL expression was also cytoplasmic with no 
nuclear expression. A distinct membranous positivity emerged in many 
cases, regardless of cytoplasmic staining intensity. Cytoplasmic staining was 
scored as negative (0), weakly positive (1), moderately positive (2), or 
strongly positive (3) according to staining intensity. For cases with 
membranous staining by the pAb, the score was recorded as 3, regardless of 
cytoplasmic staining intensity.  
 
In Study II, cytoplasmic staining of PROX1 and β-catenin was scored as 
negative (0), weakly positive (1), moderately positive (2), or strongly positive 
(3) according to staining intensity. With β-catenin, also membranous 
staining was evaluated. In the samples with no membranous staining, there 
was no cytoplasmic staining either. 
 
In Study III, cytoplasmic and membranous staining of UCHL5 was scored 
separately. According to staining intensity, cytoplasmic staining was scored 
as negative (0), low positive (1), moderate positive (2), or high positive (3).  
Nuclear staining was scored according to the proportion of positive nuclei in 
the tumor tissue: 0% to 10% positive nuclei scored as 0, 11% to 40% as 1, 40% 
to 75% as 2, and 76% to 100% as 3.  
 
In Study IV, cytoplasmic staining of REG4 was scored as either negative or 
positive when any degree of staining was present.  
8.5 ELISA (STUDY IV) 
The REG4 sandwich ELISA assays were performed using the Human REG4 
ELISA Pair Set (SEK11186, Sino Biological Inc., Beijing, China) in accordance 
with the manufacturer’s instructions. The primary anti-REG4 antibody (2 
µg/ml in CBS buffer containing 0.05M Na2CO3, 0.05M NaHCO3, pH 9.6) was 
immobilized to a 96-well plate overnight at 4°C, after which the wells were 
blocked with 1% BSA on 0.05% TBST for one hour at RT. Serum samples of 
the 130 patients with PDAC and the 34 CP controls were diluted 1:10 in 
sample buffer (0.1% BSA in 0.05% TBST) and incubated in duplicate wells 
(100 µl per well) for 2 hours at RT. The HRP-conjugated secondary anti-
REG4 antibody (0.5 µg/ml in 0.5% BSA in 0.05% TBST) was allowed to bind 
for one hour at RT, after which TMB substrate solution was added and 
allowed to react for 20 minutes at RT. The color reaction was stopped with 1 
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N H2SO4 and the absorbance (450 nm) was measured with a Victor 1420 
Multilabel Counter (Perkin Elmer, Waltham, MA, USA).  
8.6 STATISTICAL ANALYSES 
For statistical purposes, dichotomization of tumor marker 
immunohistochemical expression was performed (Studies I-III): PODXL 
mAb expression into low (scores 0-2) and high (3), PODXL pAb expression 
into non-membranous (0-2) and membranous (3), PROX1 and β-catenin 
expression into low (0-1) and high (2-3), UCHL5 cytoplasmic expression into 
low (0-1) and high (2-3), and UCHL5 nuclear expression into negative (<10% 
nuclear positivity, score 0) and positive (>10% nuclear positivity, scores 1-3). 
These divisions were done similarly as in previous studies by 
immunohistochemistry for more reliable evaluation of the results 
[178,180,193,203,235].  
 
To evaluate different PODXL antibodies, and β-catenin and PROX1 together, 
a categorization with three classes was created (Studies I and II): low 
(PODXL mAb low, and PODXL pAb non-membranous; and PROX1 and β-
catenin low), moderate (either PODXL mAb high or PODXL pAb 
membranous; and either PROX1 or β-catenin high), and high (both PODXL 
mAb high and PODXL pAb membranous; and PROX1 and β-catenin high). 
 
The association between tumor marker expression and relevant 
clinicopathological parameters was evaluated by Fisher’s exact test or by the 
linear-by-linear test. The Spearman correlation coefficient was calculated to 
explore correlations between tumor marker expression and specific 
laboratory parameters.  
 
To determine the difference between serum REG4 levels of PDAC and CP, 
the Mann-Whitney U test was used. Higher quarter of interquartile range 
(IQR) of serum REG4 level of CP patients served as the cut-off point for 
assessing survival of PDAC patients. PDAC patients were dichotomized into a 
low (<4.10 ng/ml) and a high group (≥4.10 ng/ml) according to serum REG4 
level (Study IV). Receiver operating characteristic (ROC) curves were 
established, and the area under the curve (AUC) values calculated to evaluate 
tumor markers. By maximizing Yonden’s index, optimal cut-off values were 
determined. Multivariate logistic regression analysis was used to discover 
independent risk factors for PDAC (Study IV).  
 
Survival analyses were performed by the Kaplan-Meier method and 
compared by log-rank test or by Breslow test.  The Bonferroni correction was 
applied for multiple comparisons by dividing the probability level with the 
number of comparisons. The Cox proportional hazard model was performed 
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in uni- and multivariate analyses adjusted for age, gender, stage, lymph node 
status, perivascular invasion, and postoperative adjuvant therapy. To 
simplify the model, stage and LNR were combined into a single variable since 
they are internally correlated. Interaction terms were considered. Testing of 
the Cox model assumption of constant hazard ratios over time involved the 
inclusion of a time-dependent covariate separately for each testable variable. 
All tests were two-sided. A p-value of 0.05 or less was considered significant. 
Statistical analyses were with SPSS (IBM SPSS Statistics, for Mac/Windows; 
SPSS, Inc., Chicago, IL, USA).  
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9 RESULTS 
9.1 IMMUNOHISTOCHEMISTRY 
9.1.1 PODXL (STUDY I) 
PODXL expression by the pAb was cytoplasmic in tumor cells, but in some 
specimens, a distinct membranous expression pattern was apparent, which 
did not correlate with intensity of the cytoplasmic expression. Such a staining 
pattern was not visible for the mAb; instead the staining was cytoplasmic and 
evenly distributed. 
 
PODXL staining by the pAb could be evaluated in 166 specimens (98.8%): 13 
(7.8%) showing negative, 71 (42.8%) weak, 55 (33.1%) moderate, and 27 
(16.3%) strong staining. By the pAb, non-membranous staining was 
evaluated in 93 specimens (56.0%), and membranous staining in 73 
specimens (44.0%).  PODXL staining by the mAb was evaluated in 165 
specimens (98.2%): 21 (12.7%) showing negative, 69 (41.8%) weak, 39 
(23.6%) moderate, and 36 (21.8%) strong staining. Expression of each tumor 
marker is presented in Table 7, and representative staining patterns are 
illustrated in Figure 3.  
 
 
Figure 3.  Immunohistochemical staining pattern of PODXL by polyclonal 
antibody HPA2110 and by monoclonal antibody HES9 in pancreatic ductal 
adenocarcinoma. Representative images of PODXL expression in PDAC by 
pAb HPA2110 from A to D (negative-weak-moderate-strong). Representative 
images of PODXL expression in PDAC by mAb HES9 from E to H (negative-
weak-moderate-strong). Modified from Study I with permission by Creative 
Commons (CC) BY. 
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9.1.2 PROX1 AND β-CATENIN (STUDY II) 
PROX1 expression was evenly distributed in the cytoplasm without 
distinctive membranous staining. In normal pancreatic tissue at the edge of 
the tumor, clear nuclear staining was present, even though all of the nuclei 
were not stained. We detected staining of the nuclei in two cancer tissue 
samples, and the cytoplasmic staining scores in these samples were 1 and 3. 
Otherwise, cancer specimens were negative for nuclear staining. In the whole 
tumor specimens, no nuclear staining was present in metastases, as only 
negative or weak cytoplasmic staining was present (Figure 4). 
 
β-catenin expression was present both in the cell membrane and within the 
cytoplasm. In few exceptions, the staining was not uniform in the tumor cell. 
Cytoplasmic staining was stronger with more intense membranous staining. 
Cytoplasmic expression pattern showed two different staining types: 
homogeneous and granular.  Nuclear staining was not seen and only three 
specimens lacked membranous staining (Figure 4). Scoring membranous 
and cytoplasmic staining separately was not possible. Therefore, cytoplasmic 
expression was used in statistical analyses. 
 
 
 
Figure 4.  Immunohistochemical staining pattern of PROX1 in normal 
pancreatic tissue (A), in the transitional zone of normal pancreatic tissue and 
cancerous tissue (B), and in metastasized lymph node (C-D). 
Immunohistochemical staining pattern of β-catenin in normal pancreatic 
tissue (E). Weak cytoplasmic β-catenin expression positivity in PDAC with no 
membranous expression (F), and with some membranous positivity (G). 
Moderate cytoplasmic β-catenin expression in PDAC (H). Modified from 
Study II with permission by CC BY. 
 
PROX1 staining was evaluable in the tumor tissue of 154 specimens (98.7%): 
20 (13.0%) showing negative, 60 (39.0%) weak, 66 (42.9%) moderate, and 8 
(5.2%) strong staining (Table 7). β-catenin cytoplasmic staining was 
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evaluable in 153 specimens (98.1%): 1 (0.7%) showing negative, 52 (34.0%) 
weak, 63 (41.2%) moderate, and 37 (24.2%) strong staining (Table 7). 
Combined PROX1 and β-catenin expression was evaluated in 152 tumors 
(97.4%): 38 (25.0%) showing low, 56 (36.8%) moderate, and 58 (38.2%) high 
staining pattern. 
 
 
 
Figure 5. Immunohistochemical staining pattern of PROX1 and β-catenin 
expression in PDAC. Negative (A), weak (B), moderate (C), and strong (D) 
cytoplasmic PROX1 expression. Negative (E), weak cytoplasmic and 
membranous (F), moderate cytoplasmic (G), and strong cytoplasmic and 
membranous positivity (H) of β-catenin expression. Modifed from Study II 
with permission by CC BY. 
9.1.3 UCHL5 (STUDY III) 
When cytoplasmic UCHL5 expression was observed, the staining was 
uniform and ubiquitous throughout the tumor tissue (Figure 6). Cytoplasmic 
and nuclear UCHL5 expression could be evaluated in the tumor tissue of 153 
specimens (99.4%). The cytoplasmic immunoexpression was negative in 94 
(61.4%), low in 51 (33.3%), moderate in 7 (4.6%), and strongly positive in 1 
(0.7%) specimen. Nuclear expression was evaluated according to the 
proportion of positive nuclei in the tumor tissue as 0 in 74 (48.4%), as 1 in 50 
(32.7%), as 2 in 20 (13.1%), and as 3 in 9 (5.9%) tumor specimens (Table 7).  
 
The one patient with strong cytoplasmic UCHL5 expression scored 3 for 
nuclear expression, while the seven patients with moderate cytoplasmic 
expression scored mainly 0 or 1. Normal-appearing cells next to the tumor 
tissue showed principally low or negative cytoplasmic staining and a low 
proportion of nuclear positive staining.  
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Figure 6. Immunohistochemical staining pattern of UCHL5 expression in 
PDAC and in normal pancreatic tissue. Negative-low-moderate-strong 
cytoplasmic UCHL5 expression (A-D). Positive nuclear UCHL5 expression 
(E). UCHL5 staining in normal-appearing pancreatic tissue next to the tumor 
tissue (F). Modified from Study III with permission by CC BY NC. 
 
9.1.4 REG4 (STUDY IV) 
Positive REG4 immunoexpression in the tumor cells was cytoplasmic with a 
granular distribution when present. Expression was predominantly located 
on the apical cell surface with no distinct nuclear expression (Figure 7). 
 
Immunostaining was evaluable in 153 cases (99.4%): 110 (71.9%) were 
negative and 43 (28.1%) positive (Table 7).  
 
 
 
Figure 7. Immunohistochemical staning pattern of REG4 expression. 
Negative (A) and positive (B) tissue REG4 expression in PDAC. Modified 
from Study IV with permission by CC BY NC. 
 51 
 
 
Table 7. Immunohistochemical expression of the studied tumor markers in 
pancreatic ductal adenocarcinoma.  
Marker 
expression  Staining pattern 
 Patients N (%)    
PODXL 
pAb 
 Non-
membranous 
  Membranous 
 166 93 (56.0)   73 (44.0) 
PODXL 
mAb  Negative Weak Moderate Strong 
 165 21 (12.7) 69 (41.8) 39 (23.6) 36 (21.8) 
PROX1  Negative Weak Moderate Strong 
 154 20 (13.0) 60 (39.0) 66 (42.9) 8 (5.2) 
β-catenin  Negative Weak Moderate Strong 
 153 1 (0.7) 52 
(34.0) 
63 (41.2) 37 (24.2) 
UCHL5 
cytoplasmic  Negative Weak Moderate Strong 
 153 94 (61.4) 
51 
(33.3) 7 (4.6) 1 (0.7) 
UCHL5 
nuclear  0 1 2 3 
 153 74 (48.4) 50 (32.7) 20 (13.1) 9 (5.9) 
REG4  Negative   Positive 
 153 110 (71.9)   43 (28.1) 
Abbreviations: pAb = polyclonal antibody, mAb = monoclonal antibody 
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9.2 ASSOCIATION OF BIOMARKER EXPRESSION WITH 
CLINICOPATHOLOGICAL PARAMETERS (STUDIES 
I-IV) 
Membranous PODXL expression by the pAb was associated significantly with 
advanced T stage of the tumor (p=0.045) and with positive perineural 
invasion (p=0.005) (Table 8). High PODXL expression by the mAb was 
associated with poor differentiation of the tumor (p=0.033). Combined 
PODXL expression with both the pAb and the mAb was associated with poor 
differentiation of the tumor (p=0.014) and with positive perineural invasion 
(p=0.007).  
 
For PROX1 expression, a significant association was detected with age; 
patients with low PROX1 expression were younger than patients with high 
PROX1 expression (p=0.038) (Table 9). Low β-catenin expression was 
associated with poor differentiation of the tumor (p=0.025). PROX1 and β-
catenin expression correlated with each other (Spearman correlation 
coefficient=0.371; 95% CI 0.24-0.50; p<0.001). 
 
Patients with positive nuclear UCHL5 expression had smaller tumors than 
patients with negative nuclear UCHL5 expression (p=0.018), and these 
patients were also significantly older (p=0.004) (Table 10). Cytoplasmic and 
nuclear UCHL5 expression showed no significant correlation with each other 
(p=0.117; Spearman correlation). 
 
Tissue REG4 expression was associated with tumor histological grade; 
patients with positive tissue REG4 expression had more differentiated 
tumors than patients with negative tissue REG4 expression (p=0.025) (Table 
11). Serum REG4 level showed no significant associations with ordered 
parameters. 
 
 
 
 
 
 
 
 
 53 
Table 8. Association of clinicopathological parameters with PODXL 
expression by pAb HPA2110, mAb HES9, and their combination in PDAC. 
 PODXL expression by pAb PODXL expression by mAb Combined PODXL expression 
 Non-membranous Membranous  Low High  Low Moderate High  
n(%) 93 (56.0) 73 (44.0) p 129 (78.2) 36 (21.8) p 
87 
(53.0) 45 (27.4) 32 (19.6) p 
Age, years 
<65 46 (49.5) 36 (49.3) 1.000 63 (48.8) 18 (50.0) 1.000 43 (49.4) 22 (48.9) 16 (50.0) 1.000 
≥65 47 (50.5) 37  (50.7)  66 (51.2) 18 (50.0)  44 (50.6) 23 (51.1) 16 (50.0)  
Gender 
Male 52 (55.9) 40 (54.8) 1.000 73 (56.6) 18 (50.0) 0.570 50 (57.5) 24 (53.3) 17 (53.1) 0.689 
Female 41 (44.1) 33 (45.2)  56 (43.4) 18 (50.0)  37 (42.5) 21 (46.7) 15 (46.9)  T 
1 10 (11.0) 2 (2.7) 0.045 10 (7.9) 2 (5.7) 0.776 10 (11.7) 0 (0.0) 2 (6.3) 0.227 
2 25 (27.5) 18 (24.7)  31 (24.4) 12 (34.3)  22 (25.9) 12 (26.7) 9 (28.1)  3 54 (59.3) 50 (68.5)  83 (65.4) 21 (60.0)  52 (61.2) 31 (68.9) 20 (62.5)  4 2 (2.2) 3 (4.1)  3 (2.3) 1 (2.9)  1 (1.2) 2 (4.4) 1 (3.1)  Missing 2   2 1  2    N 
0 26 (28.6) 23 (31.5) 0.733 38 (29.9) 11 (30.6) 1.000 25 (29.4) 14 (31.1) 10 (31.3) 0.829 
1 65 (71.4) 50 (68.5)  89 (70.1) 25 (69.4)  60 (70.6) 31 (68.9) 22 (68.7)  Missing 2   2   2    Stage (AJCC 7th edition) 
IA 7 (7.9) 2 (2.8) 0.606 7 (5.6) 2 (5.6) 0.531 7 (8.4) 0 (0.0) 2 (6.3) 0.419 
IB 9 (10.1) 9 (12.3)  15 (12.0) 3 (8.3)  8 (9.7) 8 (17.8) 2 (6.3)  IIA 10 (11.2) 10 (13.7)  16 (12.8) 4 (11.1)  10 (12.0) 6 (13.3) 4 (12.5)  IIB 58 (65.2) 46 (63.0)  80 (64.0) 24 (66.6)  54 (65.1) 28 (62.2) 21 (65.6)  III 0 (0.0) 3 (4.1)  2 (1.6) 1 (2.8)  0 (0.0) 2 (4.5) 1 (3.1)  IV 5 (5.6) 3 (4.1)  5 (4.0) 2 (5.6)  4 (4.8) 1 (2.2) 2 (6.3)  Missing 4   4   4    Lymph node ratio 
<20% 68 (75.6) 56 (77.8) 0.852 96 (76.8) 27 (75.0) 0.826 63 (75.0) 35 (79.5) 24 (75.0) 0.907 
≥20% 22 (24.4) 16 (22.2)  29 (23.2) 9 (25.0)  21 (25.0) 9 (20.5) 8 (25.0)  Missing 3 1  4   3 1   Grade 
1 17 (21.2) 7 (11.1) 0.103 20 (18.2) 4 (12.5) 0.033 16 (21.6) 5 (12.8) 3 (10.7) 0.014 
2 53 (66.3) 44 (69.8)  78 (70.9) 18 (56.3)  51 (68.9) 28 (71.8) 17 (60.7)  3 10 (12.5) 12 (19.1)  12 (10.9) 10 (31.2)  7 (9.5) 6 (15.4) 8 (28.6)  Missing 13 10  19 4  13 6 4  Perineural invasion 
Yes 51 (67.1) 57 (87.7) 0.005 80 (73.4) 27 (87.1) 0.151 48 (67.6) 32 (75.0) 26 (92.9) 0.007 
No 25 (22.9) 8 (12.3)  29 (26.6) 4 (12.9)  23 (32.4) 8 (25.0) 2 (7.1)  Missing 17 8  20 5  16 5 4  Perivascular invasion 
Yes 23 (30.7) 26 (43.3) 0.151 32 (30.8) 15 (50.0) 0.081 19 (27.1) 15 (41.7) 13 (48.1) 0.039 
No 52 (69.3) 34 (56.7)  72 (69.2) 15 (50.0)  51 (72.9) 21 (58.3) 14 (51.9)  Missing 18 13  25 6  17 9 5  
Fisher’s exact test was used for 2x2 tables, and the linear-by-linear association test 
for tables with more than two rows. Missing data were excluded from the analyses. 
Modified from Study I with permission by CC BY. 
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Table 9. Association of clinicopathological parameters with PROX1 
expression, β-catenin expression, and their combined expression. 
 PROX1 expression β-catenin expression 
Combined PROX1 and  β-catenin 
expression 
 Low High  Low High  Low Moderate High  
n(%) 80 (51.9) 74 (48.1) p 53 (34.6) 100 (65.4) p 
38 
(25.0) 56 (36.8) 58 (38.2) p 
Age, years 
<65 46 (57.5) 30 (40.5) 0.038 28 (52.8) 48 (48.0) 0.613 21 (55.3) 32 (57.1) 23 (39.7) 0.121 
≥65 34 (42.5) 44  (59.5)  25 (47.2) 52 (52.0)  17 (44.7) 24 (42.9) 35 (60.3)  
Gender 
Male 45 (56.3) 40 (54.1) 0.871 32 (60.4) 52 (52.0) 0.394 23 (60.5) 31 (55.4) 30 (51.7) 0.409 
Female 35 (43.7) 34 (45.9)  21 (39.6) 48 (48.0)  15 (39.5) 25 (44.6) 28 (48.3)  T 
1 5 (6.3) 7 (9.5) 0.274 3 (5.7) 8 (8.0 0.602 2 (5.3) 4 (7.1) 5 (8.6) 0.343 
2 18 (22.5) 22 (29.7)  14 (26.4) 26 (26.0)  10 (26.3) 12 (21.4) 18 (31.0)  3 56 (70.0) 43 (58.1)  34 (64.2) 65 (65.0)  25 (65.8) 39 (69.6) 34 (58.6)  4 1 (1.3) 2 (2.7)  2 (3.8) 1 (1.0)  1 (2.6) 1 (1.8) 1 (1.7)  N 
0 23 (28.8) 25 (33.8) 0.602 15 (28.3) 32 (32.0) 0.714 10 (26.3) 17 (30.4) 20 (34.5) 0.436 
1 57 (71.2) 49 (66.2)  38 (71.7) 68 (68.0)  28 (73.7) 39 (69.6) 38 (65.5)  Stage (AJCC 7th edition) 
IA 4 (5.0) 5 (6.8) 0.550 3 (5.7) 6 (6.0) 0.590 2 (5.3) 3 (5.4) 4 (6.9) 0.412 
IB 8 (10.0) 10 (13.5)  6 (11.3) 12 (12.0)  4 (10.5) 6 (10.7) 8 (13.8)  IIA 11 (13.8) 9 (12.2)  5 (9.4) 14 (14.0)  4 (10.5) 7 (12.5) 8 (13.8)  IIB 56 (70.0) 48 (64.9)  37 (69.8) 67 (67.0)  27 (71.1) 39 (69.6) 37 (63.8)  III 1 (1.3) 2 (2.7)  2 (3.8) 1 (1.0)  1 (2.6) 1 (1.8) 1 (1.7)  Lymph node ratio 
<20% 57 (71.3) 60 (83.3) 0.086 40 (75.5) 77 (78.6) 0.687 29 (76.3) 38 (67.9) 49 (87.5) 0.138 
≥20% 23 (28.7) 12 (16.7)  13 (24.5) 21 (21.4)  9 (23.7) 18 (32.1) 7 (12.5)  Missing  2   2    2  Grade 
1 10 (14.7) 12 (19.0) 0.543 5 (10.9) 17 (19.8) 0.025 4 (12.5) 7 (14.0) 11 (22.4) 0.059 
2 47 (69.1) 42 (66.7)  29 (63.0) 60 (69.8)  20 (62.5) 36 (72.0) 33 (67.3)  3 11 (16.2) 9 (14.3)  12 (26.1) 9 (10.5)  8 (25.0) 7 (14.0) 5 (10.2)  Missing 12 11  7 14  6 6 9  Perineural invasion 
Yes 49 (73.1) 51 (82.3) 0.291 34 (77.3) 66 (77.6) 1.000 25 (73.5) 32 (76.2) 42 (80.8) 0.438 
No 18 (26.9) 11 (17.7)  10 (22.7) 19 (22.4)  9 (26.5) 10 (23.8) 10 (19.2)  Missing 13 12  9 15  4 14 6  Perivascular invasion 
Yes 23 (36.9) 19 (32.2) 0.706 19 (43.2) 24 (30.0) 0.169 13 (38.2) 17 (42.5) 13 (26.5) 0.247 
No 41 (63.1) 40 (67.8)  25 (56.8) 56 (70.0)  21 (61.8) 23 (57.5) 36 (73.5)  Missing 15 15  9 20  4 16 9  
Fisher’s exact test was used for 2x2 tables, and the linear-by-linear association test 
for tables with more than two rows. Missing data were excluded from the analyses. 
Modified from Study II with permission by CC BY. 
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Table 10. Association of UCHL5 cytoplamic and nuclear expression with 
clinicopathological parameters. 
 UCHL5 cytoplasmic expression UCHL5 nuclear expression 
 Low High p Negative Positive p 
n (%) 145 (94.7) 8 (5.3)  74 (48.4) 79 (51.6)  
Age (years) 
<65 43 (29.7) 0 (0.0) 0.106 29 (39.2) 14 (17.7) 0.004 
≥65 102 (70.3) 8 (100.0)  45 (60.8) 65 (82.3)  
Gender 
Male 78 (53.8) 6 (75.0) 0.295 40 (54.1) 44 (55.7) 0.872 
Female 67 (46.2) 2 (25.0)  34 (45.9) 35 (44.3)  
T 
1 10 (6.9) 1 (12.5) 1.000 2 (2.7) 9 (11.4) 0.018 
2 39 (26.9) 1 (12.5)  17 (23.0) 23 (29.1)  
3 93 (64.1) 6 (75.0)  53 (71.6) 46 (58.2)  
4 3 (2.1) 0 (0.0)  2 (2.7) 1 (1.3)  
N 
0 44 (30.3) 4 (50.0) 0.260 21 (28.4) 27 (34.2) 0.488 
1 101 (69.7) 4 (50.0)  53 (71.6) 52 (65.8)  
Stage (AJCC  7th edition) 
IA 9 (6.2) 1 (12.5) 0.341 2 (2.7) 8 (10.1) 0.237 
IB 16 (11.0) 1 (12.5)  10 (13.5) 7 (8.9)  
IIA 18 (12.4) 2 (25.0)  8 (10.8) 12 (15.2)  
IIB 99 (68.3) 4 (50.0)  52 (70.3) 51 (64.6)  
III 3 (2.1) 0 (0.0)  2 (2.7) 1 (1.3)  
Lymph node ratio 
<20% 111 (77.1) 7 (87.5) 0.685 53 (72.6) 65 (82.3) 0.175 
≥20% 33 (22.9) 1 (12.5)  20 (27.4) 14 (17.7)  
Missing 1   1   
Grade 
1 17 (13.5) 1 (16.7) 1.000 6 (9.1) 12 (18.2) 0.258 
2 90 (71.4) 4 (66.7)  49 (74.2) 45 (68.2)  
3 19 (15.1) 1 (16.7)  11 (16.7) 9 (13.6)  
Missing 19 2  8 13  
Perineural invasion 
Yes 97 (78.9) 4 (57.1) 0.185 49 (76.6) 52 (78.8) 0.834 
No 26 (21.1) 3 (42.9)  15 (23.4) 14 (21.2)  
Missing 22 1  10 13  
Perivascular invasion 
Yes 41 (34.5) 2 (33.3) 1.000 20 (33.3) 23 (35.4) 0.852 
No 78 (65.5) 4 (66.7)  40 (66.7) 42 (64.6)  
Missing 26 2  14 14  
Fisher’s exact test served for 2x2 tables and the linear-by-linear association test for 
tables with more than two rows. Missing data were excluded from the analyses. 
Modified from Study III with permission by CC BY NC. 
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Table 11. Association of tissue REG4 expression and serum REG4 levels 
with clinicopathological parameters. 
 Tissue REG4 expression Serum REG4 level 
 Negative Positive p Low High p 
n (%) 110 (71.9) 43 (28.1)  60 (46.2) 70 (53.8)  
Age (years) 
<65 34 (30.9) 9 (20.9) 0.238 16 (26.7) 23 (32.9) 0.565 
≥65 76 (69.1) 34 (79.1)  44 (73.3) 47 (67.1)  
Gender 
Male 63 (57.3) 21 (48.8) 0.371 32 (53.3) 44 (62.9) 0.289 
Female 47 (42.7) 22 (51.2)  28 (46.7) 26 (37.1)  
T 
1 7 (6.4) 4 (9.3) 0.892 4 (6.7) 3 (4.3) 0.203 
2 30 (27.3) 10 (23.3)  19 (31.7) 16 (22.9)  
3 72 (65.5) 27 (62.8)  36 (60.0) 49 (70.0)  
4 1 (0.9) 2 (4.7)  1 (1.7) 2 (2.9)  
N 
0 35 (31.8) 13 (30.2) 1.000 18 (30.0) 19 (27.1) 0.846 
1 75 (68.2) 20 (69.8)  42 (70.0) 51 (62.9)  
Stage (AJCC 7th edition) 
IA 7 (6.4) 3 (7.0) 0.640 3 (5.0) 3 (4.3) 0.844 
IB 13 (11.8) 4 (9.3)  7 (11.7) 7 (10.0)  
IIA 15 (13.6) 5 (11.6)  7 (11.7) 10 (14.3)  
IIB 74 (67.3) 29 (67.4)  42 (70.0) 48 (68.6)  
III 1 (0.9) 2 (4.7)  1 (1.7) 2 (2.9)  
Lymph node ratio 
<20% 85 (77.3) 33 (78.6) 1.000 48 (80.0) 51 (73.9) 0.531 
≥20% 25 (22.7) 9 (21.4)  12 (20.0) 18 (26.1)  
Missing  1   1  
Grade 
1 7 (6.4) 11 (26.2) 0.025 9 (15.3) 6 (8.6) 0.132 
2 84 (76.4) 25 (59.5)  43 (72.9) 50 (71.4)  
3 19 (17.3) 6 (14.3)  7 (11.9) 14 (20.0)  
Missing  1  1   
Perineural invasion 
Yes 75 (81.5) 26 (68.4) 0.111 38 (73.1) 46 (79.3) 0.504 
No 17 (18.5) 12 (31.6)  14 (26.9) 12 (20.7)  
Missing 18 5  8 12  
Perivascular invasion 
Yes 33 (37.1) 10 (27.8) 0.407 19 (38.0) 18 (32.1) 0.547 
No 56 (62.9) 26 (72.2)  31 (62.0) 38 (67.9)  
Missing 21 7  10 14  
Fisher’s exact test served for 2x2 tables and the linear-by-linear association test for 
tables with more than two rows. Missing data were excluded from analyses. 
Modified from Study IV with permission by CC BY NC. 
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9.3 SURVIVAL ANALYSES 
9.3.1 PODXL (STUDY I) 
For patients with membranous PODXL expression by the pAb, CSS was 
significantly poorer than for patients with non-membranous PODXL 
expression (p=0.006, Figure 8A). Five-year CSS in the membranous PODXL 
expression group was 14.0% (95% CI 5.2-22.8%) and in the non-
membranous PODXL expression group 24.8% (95% CI 15.0-34.6%).  
 
PDAC patients with high PODXL expression by the mAb had significantly 
poorer cancer-specific survival (CSS) than patients with low PODXL 
expression (p=0.001) (Figure 8B). Five-year CSS for PDAC patients with high 
PODXL expression was 4.4% (95% CI -3.6-12.4%) and for those with low 
PODXL expression 24.8% (95% CI 16.4-33.3%).  
 
The combination of the mAb and the pAb PODXL expression showed a 
significantly poorer CSS for patients with high combined expression than for 
those with low combined expression (p=0.001, Figure 8C). Such a survival 
difference was not detected between patients with moderate and high 
combined expression (p=0.37), or between patients with moderate and low 
combined expression (p=0.020, Bonferroni correction). Five-year CSS for 
patients with combined high expression was 5.0% (95% CI -4.2-14.2%), for 
patients with moderate expression 18.7% (95% CI 6.5-30.9%), and for 
patients with low expression 26.6% (95% CI 16.2-37.0%). 
 
Cox regression uni- and multivariate analyses confirmed these results. In 
multivariate analyses, high PODXL expression by the mAb and membranous 
PODXL expression by the pAb were independent markers of poor prognosis 
in PDAC (HR=2.36, 95% CI 1.47-3.80, p<0.001; and HR=2.03, 95% CI 1.32-
3.13, p=0.001, respectively). Their combination was also an independent 
marker of poor prognosis in PDAC (moderate vs. low HR=2.07, 95% CI 1.25-
3.44, p=0.005; and high vs. low HR=2.67, 95% CI 1.55-4.59, p<0.001). The 
multivariate analysis is presented in Table 12. 
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Figure 8. Cancer-specific survival according to the Kaplan-Meier method 
for PODXL expression by pAb HPA2110 (A), by mAb HES9 (B), and by 
combined pAb and mAb (C). Modified from Study I with permission by CC 
BY. 
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9.3.2 PROX1 AND β-CATENIN (STUDY II) 
Five-year CSS did not differ significantly between PDAC patients with low 
PROX1 expression and those with high PROX1 expression (p=0.174, Figure 
9A). Five-year CSS for PDAC patients with low PROX1 expression was 15.5% 
(95% CI 6.7-24.3%) and for patients with high PROX1 expression, 20.0% 
(95% CI 9.2-30.8%). 
 
In PDAC patients with low β-catenin expression, five-year CSS was 
significantly poorer than in patients with high β-catenin expression 
(p=0.007, Figure 9B). CSS for PDAC patients with low β-catenin expression 
was 11.3% (95% CI 2.1-20.5%) and 22.4% (95% CI 13.0-31.8%) for those with 
high β-catenin expression. 
 
Combined low expression of PROX1 and β-catenin showed significantly 
poorer survival for PDAC patients than combined high expression (p=0.013, 
Figure 9C). Between patients with combined moderate and low expression 
(p=0.092), and patients with combined moderate and high expression 
(p=0.435), no significant difference in CSS was seen. Five-year CSS for 
patients with combined low expression was 10.3% (95% CI -0.7-21.3%), for 
patients with combined moderate expression 18.7% (95% CI 9.9-29.5%), and 
for patients with combined high expression 21.3% (95% CI 8.1-34.5%). 
 
Multivariate analysis showed that both high PROX1 expression (HR=0.63, 
95% CI 0.42-0.95, p=0.026) and high β-catenin expression (HR=0.54, 95% 
CI 0.35-0.82; p=0.004) were independent markers of better prognosis in 
PDAC (Table 13). The combined high expression of PROX1 and β-catenin 
also independently showed better prognosis in PDAC (HR=0.46, 95% CI 
0.28-0.76, p=0.002). 
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Figure 9. Cancer-specific survival analysis according to the Kaplan-Meier 
method in PDAC for PROX1 expression (A), for β-catenin expression (B), and 
for their combined expression (C). Modified from Study II with permission 
by CC BY. 
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9.3.3 UCHL5 (STUDY III) 
PDAC patients with either high cytoplasmic UCHL5 expression (p=0.034) or 
positive nuclear UCHL5 expression (p=0.005) had significantly better five-
year CSS. Five-year CSS for patients with high cytoplasmic expression was 
57.1% (95% CI 17.2-83.7%) and for patients with low cytoplasmic expression 
18.1% (95% CI 12.2-24.9%) (Figure 10A). For patients with positive nuclear 
UCHL5 expression five-year CSS was 22.1% (95% CI 13.5-32.1%) and for 
those with negative expression 17.4% (95% CI 9.7-27.0%) (Figure 10B).  
 
Tumor stage categorization demonstrated a more explicit beneficial survival 
trend with nuclear UCHL5 expression. Differences in survival were not 
significant in patients with stage IA-IIA disease. However, in stage IIB-III 
patients with positive nuclear expression five-year CSS was 19.9% (95% CI 
10.2-31.9%), whereas in patients with negative expression CSS was 10.4% 
(95% CI 3.8-20.8%, p=0.007) (Figure 10C). For patients over 65 years and 
with positive nuclear UCHL5 expression five-year CSS was 19.1% (95% CI 
10.3-29.8%) relative to 13.1% (95% CI 5.2-25.1%) for those with negative 
expression (p<0.001) (Figure 10D). Furthermore, in the subgroup of patients 
over 65 years, five-year CSS was 15.4% (95% CI 6.3-28.4%) for those with 
stage IIB-III disease and positive nuclear expression, relative to 8.1% (95% 
CI 1.7-21.3%, p=0.002) for those with negative expression (Figure 10E). Also, 
in the subgroup of lymph node-positive patients, a significant survival 
difference was detected. Patients in this subgroup with positive nuclear 
UCHL5 expression had five-year CSS of 19.9% (95% CI 10.2-31.9%), while 
patients with negative expression had CSS of 10.6% (95% CI 3.9-21.2%, 
p=0.006) (Figure 10F).  
 
Cytoplasmic UCHL5 expression was not an independent prognostic factor in 
multivariate analysis (HR=0.47, 95% CI 0.17-1.29, p=0.144). However, 
positive nuclear UCHL5 expression independently predicted better survival 
(HR=0.63, 95% CI 0.44-0.90, p=0.012) (Table 14).  
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Figure 10. Cancer-specific survival according to the Kaplan-Meier method 
in PDAC for cytoplasmic UCHL5 expression (A) and for nuclear UCHL5 
expression (B). Cancer-specific survival in subgroups of patients with stage 
IIB-III disease (C), patients over 65 years (D), patients over 65 years and 
with stage IIB-III disease (E), and patients with lymph node-positive disease 
(F). Modified from Study III with permission by CC BY NC. 
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Table 14. Cox multivariate analysis of relative risk of death from PDAC by 
UCHL5 expression. 
 Nuclear UCHL5 
expression 
Cytoplasmic UCHL5 
expression 
 HR (95% CI) P-value HR (95% CI) P-value 
UCHL5 expression 
Negative/Low 1.00  1.00  
Positive/High 0.63 (0.44-0.90) 0.012 0.47 (0.17-1.29) 0.144 
Age 
<65 1.00  1.00  
≥65 1.18 (0.93-1.49) 0.166 1.14 (0.91-144) 0.254 
Gender 
Male 1.00  1.00  
Female 0.91 (0.63-1.32) 0.615 0.97 (0.67-1.40) 0.868 
Stage and LNR 
IA-IIA 1.00  1.00  
IIB-III and LNR < 20% 1.59 (1.01-2.49) 0.046 1.55 (0.98-2.44) 0.060 
IIB-III and LNR ≥ 20% 3.36 (2.02-5.60) <0.001 3.04 (1.83-5.05) <0.001 
Postoperative adjuvant therapy 
No 1.00  1.00  
Yes 0.65 (0.45-0.94) 0.021 0.71 (0.49-1.03) 0.068 
Abbreviations: HR = hazard ratio, CI = confidence interval, LNR = lymph node 
ratio. Modified from Study III with permission by CC BY NC. 
 
 
9.3.4 REG4 (STUDY IV) 
Neither negative nor positive REG4 tissue expression predicted survival 
differences in PDAC patients (p=0.496, Figure 11A). Five-year CSS for 
patients with negative REG4 tissue expression was 19.7% (95% CI 12.1-
27.3%) and for patients with positive expression 20.1% (95% CI 7.8-32.4%). 
 
Likewise, CSS did not differ between patients with high and low serum REG4 
level (p=0.146) (Figure 11B). Five-year CSS for patients with high serum 
REG4 level was 16.2% (95% CI 7.4-25.0%) relative to 25.5% (95% CI 14.1-
36.9%) for those with low serum REG4 level. 
 
Tumor stage division created a survival benefit in the subgroup of patients 
with non-metastasized stage IA-IIA disease by serum REG4 level (p=0.046) 
(Figure 11C). Five-year CSS for patients with high serum REG4 level was 
21.3% (95% CI 2.9-39.7%) relative to 52.9% (95% CI 29.2-76.6%) for those 
with low serum REG4 level.  
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In patients with histological grade I disease, positive tissue REG4 expression 
favoured better prognosis when relative to negative tissue expression (five-
year CSS 36.4% vs. 0.0%, p=0.006, Figure 11D). No such difference was 
detected in patients with histological grade II-III. 
 
In multivariate analysis, neither tissue REG4 expression nor serum REG4 
level was an independent prognostic factor (HR=0.87, 95% CI 0.55-1.35, 
p=0.528; and HR=1.18, 95% CI 0.78-1.78, p=0.417, respectively) (Table 15). 
However, a significant interaction occurred between grade and tissue REG4 
expression. The interaction model suggested that positive tissue REG4 
expression was a protective factor for survival in patients with grade I disease 
(HR=0.14, 95% CI 0.03-0.68, p=0.015).  
 
 
 
 
 
Figure 11. Cancer-specific survival in PDAC according to the Kaplan-Meier 
method for tissue REG4 expression (A), serum REG4 level (B), serum REG4 
level in patients with stage IA-IIA disease (C), and for tissue REG4 
expression in patients with grade I disease (D). Modified from Study IV with 
permission by CC BY NC. 
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Table 15. Cox multivariate analysis of relative risk of death from PDAC by 
REG4 expression. 
 Tissue REG4 expression Serum REG4 level 
 HR (95% CI) P-value HR (95% CI) P-value 
REG4 expression 
Negative/Low 1.00  1.00  
Positive/High 0.87 (0.55-1.35) 0.528 1.18 (0.79-1.78) 0.417 
Age 
<65 1.00  1.00 0.249 
≥65 1.20 (0.79-1.84) 0.393 1.30 (0.83-2.05)  
Gender 
Male 1.00  1.00  
Female 1.06 (0.73-1.53) 0.771 1.29 (0.85-1.96) 0.227 
Grade 
1 1.00 <0.001 1.00 0.001 
2 2.14 (1.42-3.24)  2.22 (1.38-3.59)  
3 4.59 (2.01-10.47)  4.93 (1.89-12.87)  
Stage and LNR 
IA-IIA 1.00  1.00  
IIB-III and LNR < 20% 1.55 (0.99-2.43) 0.055 1.95 (1.16-3.28) 0.012 
IIB-III and LNR ≥ 20% 3.47 (2.09-5.78) <0.001 4.18 (2.34-7.47) <0.001 
Postoperative adjuvant therapy 
No 1.00  1.00  
Yes 0.72 (0.49-1.05) 0.088 0.83 (0.55-1.27) 0.387 
Abbreviations: HR = hazard ratio, CI = confidence interval, LNR = lymph node ratio 
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9.4 SERUM REG4 LEVELS AND DIAGNOSTIC 
ACCURACY (STUDY IV) 
9.4.1 SERUM REG4 LEVELS IN PANCREATIC DUCTAL 
ADENOCARCINOMA AND CHRONIC PANCREATITIS 
We assessed serum REG4 levels in 130 PDAC patients. The median serum 
REG4 level in PDAC was 4.90 (range 1.0-59.1) ng/ml. Serum REG4 levels 
were significantly higher in PDAC patients than in CP patients (median 4.90 
vs. 3.05 ng/ml; p=0.002, Figure 12 and Table 16). Table 16 summarizes 
serum REG4 levels in different stages of PDAC. Significant differences 
between tumor stages in serum REG4 levels were not found.  
 
 
 
Figure 12. Serum REG4 levels are significantly higher in pancreatic ductal 
adenocarcinoma (PDAC) than in chronic pancreatitis (CP) (median 4.90 vs. 
3.05 ng/ml; p=0.002, Mann-Whitney test). Reprinted from Study IV with 
permission by CC BY NC. 
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Table 16. Serum REG4 levels in pancreatic ductal adenocarcinoma and in 
chronic pancreatitis. 
 REG4 level (ng/ml) p-value* 
Stage IA (n=6)  0.197 
Mean 4.45  
Median 3.80  
Range 2.1-8.4  
IQR 3.8 (1.9-5.7)  
Stage IB (n=14)  0.134 
Mean 5.10  
Median 4.34  
Range 1.5-12.4  
IQR 5.2 (1.7-6.9)  
Stage IIA (n=17)  0.007 
Mean 5.59  
Median 5.18  
Range 1.3-11.1  
IQR 4.5 (2.9-7.4)  
Stage IIB (n=90)  0.003 
Mean 5.89  
Median 4.90  
Range 1.0-59.1  
IQR 4.4 (2.7-7.1)  
Stage III (n=3)  0.293 
Mean 8.41  
Median 4.63  
Range 2.1-18.5  
IQR -  
PDAC total (n=130)  0.002 
Mean 5.76  
Median 4.90  
Range 1.0-59.1  
IQR 4.6 (2.6-7.2)  
Chronic pancreatitis (n=34)  - 
Mean 3.11  
Median 3.05  
Range 0-6.9  
IQR 2.1 (2.0-4.1)  
IQR= Interquartile range. PDAC = pancreatic ductal adenocarcinoma. *Mann-
Whitney U test was used for comparing serum REG4 levels in different stages of 
PDAC and chronic pancreatitis. Serum REG4 levels did not differ significantly 
between different stages of PDAC (data not shown). Modified from Study IV with 
permission by CC BY NC. 
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9.4.2 SERUM REG4 LEVEL AS A DIAGNOSTIC MARKER 
To evaluate and compare the diagnostic accuracy of REG4, CA19-9, and CEA, 
ROC analysis was performed. AUC value for REG4 was 0.675 (95% CI 0.587-
0.763, p=0.002), for CA19-9 0.806 (95% CI 0.737-0.874, p<0.001), and for 
CEA 0.544 (95% CI 0.437-0.650, p=0.460) (Figure 13). With an optimal cut-
off value of 5.3 ng/ml, serum REG4 sensitivity was 45% and specificity 91%. 
Serum CA19-9 had a sensitivity of 81% and a specificity of 74% with an 
optimal cut-off value of 17 kU/l.  
 
 
 
 
Figure 13. Comparison of serum REG4, CA 19-9, CEA, and calculated 
probability of cancer with Receiver Operating Characteristic (ROC) analysis 
in 130 patients with pancreatic ductal adenocarcinoma. 34 patients with 
chronic pancreatitis served as controls. AUC = area under curve; SE = 
standard error. Reprinted from Study IV with permission by CC BY NC. 
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Serum REG4 and CA19-9 were significant and independent risk factors for 
PDAC in a multivariate logistic regression model adjusted for age (Table 17). 
This suggests that their combination might be able to improve diagnostic 
accuracy. The logistic regression model achieved an AUC of 0.867 (95% CI 
0.804-0.930, p<0.001), which numerically exceeds the AUCs of REG4 and 
CA19-9 alone (Figure 13). At the optimal cut-off, sensitivity of 85% and 
specificity of 79% were achieved. 
 
Table 17. Multivariate logistic regression analysis for risk of pancreatic 
ductal adenocarcinoma (PDAC). 
Variable OR 95% CI P value 
Age 1.10 1.04-1.16 <0.001 
Serum REG4 level 7.88 1.13-54.92 0.037 
Serum CA 19-9 level 3.06 1.62-5.81 <0.001 
Logarithmic transformation performed for REG4 and CA 19-9 variables. OR = odds 
ratio; CI = confidence interval. Modified from Study IV with permission by CC BY 
NC. 
 
 
9.5 REG4 CORRELATIONS  
Tissue REG4 expression and serum REG4 level did not correlate significantly 
with each other in PDAC (p=0.289, correlation coefficient (r)=0.094, 
standard error (SE)=0.100). Neither was there a significant correlation 
between C-reactive protein (CRP) values and tissue REG4 expression 
(p=0.885, r=0.013, SE=0.096) and serum REG4 level (p=0.318, r=0.089, 
SE=0.088). Additionally, no correlation was present between CRP values 
and serum REG4 levels when classified by tumor histological grade. Serum 
REG4 level correlated with CEA level (p=0.036, r=0.188, SE=0.088), but not 
with CA19-9 (p=0.975, r=0.003, SE=0.092). CA19-9 and CEA levels did not 
differ significantly between low and high serum REG4 level groups (data not 
shown).  
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10 DISCUSSION 
10.1 PODOCALYXIN 
Study I showed PODXL to be an independent marker of poor prognosis in 
PDAC. Positive PODXL expression in PDAC has been demonstrated earlier 
[236], and it can differentiate PDAC from other adenocarcinomas occurring 
in the biliary tract [179]. However, immunopositivity of PODXL in these 
studies was only 44-69%, whereas immunopositivity of 87-92% was achieved 
in our study. Explanations for the difference may be dissimilar staining 
techniques, evaluation of specimens, cut-off points, and antibodies used. 
Immunostaining of PODXL by the new in-house mAb gave similar 
prognostic results to the commercial pAb (HPA2110). 
 
In cancer, poor prognosis may be associated with membranous PODXL 
expression rather than with cytoplasmic expression [169,237]. An earlier 
study supports these findings by demonstrating that aberrant PODXL 
expression enhances the disruption of cell-to-cell and cell-to-ECM adhesions, 
leading to tumor dissemination [238]. In PDAC, the staining pattern by the 
mAb was mainly cytoplasmic, with no clear membranous immunopositivity. 
The reason for this is unknown. The proportion of tumors with high 
cytoplasmic or membranous PODXL expression in PDAC was quite large 
(21.8% and 44.0%, respectively) compared with the corresponding 
proportions in studies of colorectal, breast, urothelial bladder, and gastric 
cancer [168-171,174,178,180]. 
 
The antibodies used in Study I recognize different epitopes of the PODXL 
molecule, which may explain the variation of their expression pattern and the 
case-by-case expression difference. The pAb may recognize an active form of 
PODXL at the cell membrane, whereas the mAb may recognize 
overexpression of cytoplasmic PODXL [178]. Patients with both high mAb 
expression and membranous pAb expression had even worse prognosis in 
CRC than patients with one of the two [178]. We found a similar trend in 
PDAC. Only a small difference was present between the two antibodies as 
prognostic markers. However, PODXL was an independent prognostic factor 
in multivariate analysis independent of the antibody. Five-year CSS was 
lower for patients with high PODXL expression by the mAb than for patients 
with membranous PODXL expression by the pAb (4.4% vs. 14.0%), which 
supports the role of cytoplasmic overexpression of PODXL as a marker of 
poor prognosis.  
 
Since our study, two studies have reinforced the hypothesis of positive 
PODXL expression being a marker of poor prognosis in pancreatic cancer 
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[181,182]. In one of these studies, membranous PODXL expression was 
shown to be an independent marker of poor prognosis in intestinal-type 
periampullary carcinomas, but not in pancreatobiliary-type carcinomas 
[181]. The problem with comparing the results is that intestinal-type 
periampullary carcinoma (derived mainly from duodenum or papilla Vateri) 
is not, de facto, pancreatic ductal in origin. PODXL is known to promote 
pancreatic cancer cell motility and invasion by binding to the cytoskeletal 
protein gelsolin [182]. It seems that both intracellular changes enhancing the 
cancer cell motility and invasion and cell-to-cell interactions leading to 
metastatic spread are important factors in pancreatic tumor advancement 
[182,236,238,239]. 
 
10.2 PROX1 AND β-CATENIN 
In Study II we showed high tissue expression of PROX1 and β-catenin 
independently to predict better prognosis in PDAC. Loss of PROX1 in the 
pancreas leads to size reduction [240], to premature acinar cell 
differentiation, and to increased ductal cell proliferation [241], which makes 
PROX1 expression vital for pancreatic development. In 2006, pancreatic 
cancer cells were demonstrated to express less PROX1 mRNA than normal 
exocrine pancreatic cells, and PROX1 gene expression levels were lower in 
pancreatic cancer patients with survival less than 6 months [202]. Our study 
showed a similar tendency by immunohistochemistry, although the 
difference in survival was not significant. To date, there are no other 
prognostic studies on PROX1 protein expression in PDAC.  
 
Increased PROX1 expression has been demonstrated to be associated with 
poor prognosis and with dedifferentiated tumor grade in CRC without being 
an independent prognostic factor [235]. These findings in CRC were contrary 
to our results in PDAC. PROX1 is considered to be required in the formation 
of lymphatic vasculature [199], and overexpression of PROX1 in blood 
endothelial cells can induce lymphatic endothelial cell gene expression [242]. 
However, active lymphangiogenesis may not be needed for lymphovascular 
spread in pancreatic cancer [202]. Recent data show positive PROX1 
expression to correlate with positive lymph node metastases in CRC [243]. In 
gastric cancer, the role of PROX1 expression in patient survival is still under 
debate since positive or high PROX1 expression has been reported to be a 
marker of both poor and favorable prognosis [203,244].  
 
We evaluated the cytoplasmic staining of PROX1, while the nuclear staining 
has been assessed in earlier studies of CRC, hepatocellular carcinoma (HCC), 
and gliomas [235,245,246]. In recent studies of gastric cancer, also 
cytoplasmic PROX1 expression by IHC was evaluated and shown to correlate 
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with PROX1 mRNA amplification [203,247]. Although nuclear staining is 
present in the normal pancreas, we noted nuclear staining in only two tumor 
specimens. Decreased nuclear expression and retained cytoplasmic 
expression of PROX1 in cancerous tissue suggest that PROX1 may not 
function as an active transcription factor in PDAC. In papillary thyroid 
cancer (PTC), the role of cytoplasmic PROX1 expression was studied, with 
the discovery that PROX1 became inactivated through mRNA 
downregulation by aberrant NOTCH signaling, and cytoplasmic 
mislocalization of PROX1 increased protein stability in PTC cells [248]. 
Restoration of PROX1 impaired tumor formation and reduced invasiveness 
of PTC cells.  
 
Whether downregulation of PROX1 in the nuclei results from the evolved 
pancreatic cancer or leads to pancreatic cancer formation remains unknown. 
We can only speculate whether cytoplasmic PROX1 in pancreatic tumor 
tissue is in active or inactive form because of the limitations of IHC. Two 
main questions remain to be clarified: the role of cytoplasmic PROX1 
expression and the signal leading to relocation of PROX1 into the cytoplasm 
[248].  
 
β-catenin expression is predominantly localized in the membrane of ductal 
cells in the normal pancreas. In pancreatic tumors, increased β-catenin 
expression and protein levels are reported [187]. However, in gene array 
analysis, inhibition of the Wnt/β-catenin signaling pathway blocked 
proliferation and induced apoptosis of cultured PDAC cells [189]. β-catenin 
expression by IHC in PDAC has been more widely studied [188,190-193,249], 
but there is considerable controversy between the results of these studies. 
Reduced or abnormal β-catenin expression predicted poor prognosis in 
PDAC patients in two studies [190,192]. Another study showed that reduced 
membranous and positive cytoplasmic expression of β-catenin was 
associacted with poorer survival in PDAC during a one-year follow-up [191]. 
One study found no prognostic impact of β-catenin cytoplasmic expression 
on survival in PDAC patients [193]. These results differ from ours. However, 
two major differences exist when comparing the results. Firstly, the follow-up 
times in these previous studies are only one or two years, and secondly, the 
patient cohorts have been small (n= 43 to 48). Our study revealed by IHC 
that β-catenin expression in PDAC is both membranous and cytoplasmic 
with no distinct nucler staining and high β-catenin expression predicts better 
prognosis. 
 
PROX1 and β-catenin expression were also studied together because they are 
linked in the same signaling pathway and their coactivation or coexpression 
is increased in CRC [194,235,250]. Moreover, it was recently shown that a 
transcriptional coactivator deleted in breast cancer (DBC1) acts as a positive 
regulator and as a key factor of the β-catenin-PROX1 signaling axis in CRC 
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progression [251]. We demonstrated by IHC that expression of both PROX1 
and β-catenin is decreased in PDAC patients, and their expression is 
correlated significantly. These results are in contrast to those in CRC. It 
remains unclear whether PROX1 and β-catenin function in a similar, albeit 
opposite, way in PDAC and CRC. We could not find any further significant 
prognostic effect with combined PROX1 and β-catenin expression relative to 
β-catenin expression alone.  
 
10.3 UCHL5 
Study III showed nuclear positive and potentially high cytoplasmic UCHL5 
expression to be markers of better prognosis in PDAC patients. For patients 
with positive nuclear UCHL5 expression, differences in survival were 
discovered in subgroups of patients over 65 years, patients with stage IIB-III 
disease, and patients with lymph node-positive disease.  
 
In pancreatic cancer samples, low to moderate staining of UCHL5 is 
distinguishable according to the Human Protein Atlas. Until now, only a few 
publications have analyzed UCHL5 by immunohistochemistry in cancer. In 
esophageal squamous cell carcinoma, while higher UCHL5 expression has 
been associated with decreased survival, UCHL5 has failed to be an 
independent prognostic factor [208]. In HCC, UCHL5 expression has been 
reported to be an independent predictive factor for cancer recurrence, but 
not for overall survival [209]. In addition, immunopositive cytoplasmic 
UCHL5 expression has been shown to be an independent factor for poor 
prognosis in epithelial ovarian cancer [210].  In contrast to this data, we have 
demonstrated that UCHL5 nuclear positivity and probably also high 
cytoplasmic expression are associated with better survival in PDAC patients. 
In order to support the survival benefit of UCHL5 immunopositivity, high as 
well as negative cytoplasmic UCHL5 expression has correlated with increased 
survival in lymph node-positive rectal cancer [211]. However, nuclear UCHL5 
positivity was infrequent in CRC. In PDAC, high cytoplasmic UCHL5 
expression appears to be associated with better survival, but the significance 
of these findings remains unknown due to the small number of patients in 
this cohort. Confirmation of this survival benefit in another PDAC patient 
cohort is required. 
 
Interacting with the proteasome, UCHL5 functions as its negative regulator 
[252]. High levels of nuclear UCHL5 may lead to disproportionate inhibition 
of the proteasome, and gradually, to accumulation of proteosomal substrates 
destructive to the cell. Molecular mechanisms of how UCHL5 functions in 
both cancerous and healthy tissues need to be clarified. Interestingly, PDAC 
patients with positive nuclear UCHL5 expression tended to be older and to 
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have smaller tumors. Aging causes disturbances in proteostasis [253], and 
dysfunction of the proteasome is associated with age-related disorders. 
Therefore, one can speculate that high UCHL5 expression reduces 
proteasome activity in the elderly, predisposing tumor cells to apoptosis.  
 
In Study II, we demonstrated that high β-catenin expression is associated 
with better survival. Because the expression levels of β-catenin are regulated 
by proteosomal degradation [254], the UCHL5-mediated decrease in 
proteasome activity might elevate β-catenin levels in tumor cells. PSCs, 
which are responsible for ECM and tumor-promoting growth factor 
production in the stroma, are involved in PDAC progression [255]. Smad7 
and TGF-β signaling were recently reported to affect PSC-induced cancer cell 
migration [256]. As UCHL5 is linked to Smad and TGF-β signaling [257-
259], it may also play a role in the desmoplastic reaction. However, this 
hypothesis requires further investigation.  
 
One decade ago, the proteasome inhibitor bortezomib was approved for 
treatment of multiple myeloma [260,261] and mantle cell lymphoma [262]. 
Proteasome inhibitors are potent therapeutic agents with a limited 
therapeutic window, dose-dependent toxicity, and marked drug resistance 
[263]. There is growing interest in alternative therapeutic agents modulating 
the UPS, including DUBs [264,265]. Pharmocological inhibition of the two 
proteasome-associated DUBs, Usp-14 and UCHL5, has been shown to 
enhance cytotoxicity in cancer cells and to inhibit tumor growth [264,266]. 
Hence, targeting proteasome-associated DUB activity may provide an 
alternative strategy to anti-cancer therapy in the future.  
 
10.4 REG4 
In Study IV, we demonstrated REG4 expression to predict survival in PDAC 
patients with early disease (stages IA-IIA) and in those with well-
differentiated tumors. Also, significant differences in serum REG4 levels 
between PDAC and CP were detected. Both REG4 and CA19-9 provided 
independent diagnostic information, which suggests that REG4 may become 
useful as a diagnostic marker in PDAC.  
 
Until now, there have been no studies showing the prognostic significance of 
REG4 expression in PDAC. Recently, low REG1A/B tissue expression was 
reported as a marker of poor prognosis in PDAC [231]. Typically, REG4 is not 
expressed in the exocrine pancreas, contrary to REG1A/B [214]. Additionally, 
the REG4 gene is located on chromosome 1, whereas other REG genes are on 
chromosome 2 [214,215]. One can hypothesize that the biological functions 
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of these proteins are distinct from each other because of the location on 
different chromosomes and encoding by different transcription factors.  
 
REG4 expression has been more widely studied in other gastrointestinal 
cancers. In CRC, high tissue REG4 expression predicts poor survival by 
immunohistochemistry [219] and by mRNA expression [218]. However, 
contradictory results also exist, as positive REG4 tissue expression was 
shown to predict better survival in non-mucinous CRC [220]. In gastric 
cancer, high tissue REG4 expression predicts poor survival [221] and 
peritoneal metastasis [222], while in gallbladder cancer, positive tissue REG4 
epression is associated with better prognosis [223]. In our study, PDAC 
patient survival did not differ significantly according to positive or negative 
tissue REG4 expression or high or low serum REG4 level.  
 
Interestingly, patients with early stage (IA-IIA) disease show better 
prognosis with lower serum REG4 levels. Animal models and cell cultures 
have demonstrated pancreatic tumors to grow larger when REG4 expression 
is introduced [227-229]. Possibly, negative or low-REG4-expressing 
pancreatic tumors grow slower and are better differentiated in humans. We 
also showed positive tissue REG4 expression to predict better prognosis in 
PDAC patients with histological grade 1 disease. The same tendency has 
previously been discovered with REG1A/B expression, but not with REG4 
expression [231].  
 
REG4 expression is also upregulated in inflammatory processes such as IBD 
[214,215]. Increased REG4 expression protects against acinar cell necrosis in 
experimental pancreatitis in mice, which suggests that REG4 may have anti-
inflammatory features [267]. We speculate that in well-differentiated 
pancreatic tumors REG4 expression may have a protective function against 
cell dedifferentiation. However, we found no correlation between histological 
grades and REG4 or CRP values. The possible anti-inflammatory role of 
REG4 warrants further investigation.  
 
We demonstrated that in PDAC and CP serum REG4 levels differ 
significantly. All patients with CP had undergone extensive surgery in order 
to exclude malignancy, but histopathology of the surgical samples confirmed 
the diagnosis of CP. To the best of our knowledge, this was the first study to 
report such a significant difference. The cut-off value for REG4 in our series 
was moderately higher than in previous studies. In one study, a cut-off point 
of 4.53 ng/ml was used, but neither sensitivity nor specificity was reported 
[226]. In another study, a cut-off point of 3.49 ng/ml with 94.0% sensitivity 
and 64.0% specificity was described [232]. Nevertheless, in both of these 
studies, patients with stage IV PDAC were included, and the comparisons of 
REG4 levels were between PDAC and healthy subjects. We excluded stage IV 
patients and compared serum REG4 levels between PDAC patients and CP 
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patients, which is a clinically more relevant comparison. This probably 
explains the differing results between these studies.  
 
In gastric cancer, REG4 has been shown to be more accurate than CEA or 
CA19-9 [268]. In ovarian cancer, REG4 expression can serve as a diagnostic 
serum biomarker for differentiating mucinous ovarian cancer from other 
epithelial ovarian cancer subtypes, and it may be useful in follow-up [269]. In 
mucinous ovarian carcinomas, serum REG4 levels were nearly 40 times 
higher than in serous ovarian carcinomas before surgery, and they declined 
rapidly after surgery. It would be interesting to study REG4 levels during 
follow-up of PDAC.  
 
10.5 STRENGTHS AND LIMITATIONS OF STUDY 
MATERIALS AND METHODS 
Patients who were treated with neoadjuvant therapy were excluded from the 
study cohort because it is largely unknown how neoadjuvant treatment 
affects the morphology of the tumor tissue. One cannot directly compare 
immunohistochemistry between patients who have received neoadjuvant 
therapy with those who have not. Evidence indicates that chemotherapeutic 
agents have immunologic effects on the tumor microenvironment [270-272], 
altering the composition of the tumor tissue. 
  
The TMA technique used in all four studies allows analysis of large patient 
cohorts with relative ease and accuracy. However, only small areas of the 
tumors are evaluated compared with whole tissue sections. By taking cores 
from different parts of the tumor, possible sampling error can be diminished. 
Only a small part of the specimens were lost in the study for technical 
reasons. The strength of this study is a rather large patient cohort with a long 
follow-up time. Sadly, due to the long period of data collection 
(approximately 10 years), some of the crucial clinicopathological parameters 
and serum samples were unavailable. Also, one of the weaknesses of the 
study is the lack of knowledge of a reliable resection margin status (R0/R1). 
This arises from the fact this study being retrospective; only in the last few 
years have clinicians and pathologists directed attention to this important 
matter. 
 
The study population was homogeneous as all histological specimens were 
re-evaluated and only ductal adenocarcinomas were included in the study. In 
Study IV, the clinical diagnostic dilemma between PDAC and CP was 
clinically relevant, bearing in mind that CP patients underwent extensive 
surgery because their diagnosis coud not be determined by preoperative 
testing. 
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10.6 CONCLUDING REMARKS 
Cancer treatment is a growing healthcare burden, and advances in 
prevention, diagnostics, and treatment methods are urgently needed. Novel 
biomarkers are critical for early detection of cancer and allocation of patients 
to more targeted and individualized therapies [82,273].  
 
This study confirmed PODXL to be a marker of poor prognosis in PDAC by 
two different antibodies, both of which recognized groups of patients with 
poor prognosis. We also showed that high tissue expression of PROX1 and β-
catenin, both independently, predicts better prognosis in PDAC. PROX1 
expression was observed to localize in the cytoplasm, whereas β-catenin 
expression localized in both the cytoplasm and the cell membrane. Study III 
demonstrated a novel prognostic biomarker, UCHL5, in subgroups of 
patients, as positive nuclear expression was associated with better prognosis. 
This finding must be validated in further studies in other patient cohorts. In 
Study IV, we demonstrated that REG4 expression in subgroups of PDAC 
patients had prognostic relevance. In addition, the study showed the possible 
utility of serum REG4 as a diagnostic marker.  
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11 CONCLUSIONS 
? PODXL was associated with unfavorable clinicopathological 
parameters and was an independent marker of poor prognosis in 
PDAC. Both membranous expression of PODXL by a polyclonal 
antibody and high cytoplasmic expression of PODXL by a monoclonal 
antibody defined groups with poor prognosis. 
 
? High tissue expression of PROX1 and β-catenin, both independently, 
predicted better prognosis in PDAC. 
 
? Positive nuclear UCHL5 expression correlated with better prognosis in 
PDAC. 
 
? REG4 expression may prove useful as a prognostic marker in PDAC 
patient subgroups, but it may also serve as a diagnostic serum 
biomarker in addition to CA 19-9.  
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